AXIM Biotechnologies (AXIM) 10-Q 20 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Oct. 17, 2023
Cover [Abstract]
Entity Registrant Name	AXIM Biotechnologies, Inc.
Entity Central Index Key	0001514946
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		237,649,403
Entity File Number	000-54296
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-4029386
Entity Address Address Line 1	6191 Cornerstone Court
Entity Address Address Line 2	E. Suite 114
Entity Address City Or Town	San Diego
Entity Address State Or Province	CA
Entity Address Postal Zip Code	92121
City Area Code	(858)
Local Phone Number	923-4422
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 23,220	$ 47,282
Prepaid expenses	0	42,858
Other Current Assets		13,839
Total current assets	23,220	103,979
Property and equipment, net of accumulated depreciation	69,410	93,840
Other Assets:
Intangible Asset , net	3,693,593	3,989,427
Security deposit	9,014	5,000
Operating lease right-of-use asset	248,719	19,789
Total other assets	3,951,326	4,014,216
TOTAL ASSETS	4,043,956	4,212,035
Current liabilities:
Accounts payable and accrued liabilities	1,421,832	1,316,248
Lease liability obligations (see Note 16) current portion	91,672	19,789
Due to first insurance funding	0	26,781
Advances from shareholder	80,170	47,720
Deferred revenue	310,688	333,125
Derivative liability conversion feature	2,373,804	1,648,831
Total current liabilities	4,278,166	3,392,494
Long-term liabilities:
Convertible note payable related party( Including accrued interest of $6861)(net of unamortized debt discount of $233,099)	23,762	0
Convertible note payable (including accrued interest of $70,061 and $274,442, respectively) net of unamortized debt discount of $1,557,786 and $1,583,435, respectively(see note 12)	1,429,684	1,383,416
Convertible note payable - related party (including accrued interest of $105,000 and $261,537, respectively)	4,105,000	4,261,537
Lease liability obligations (see Note 16)	162,410	0
Total long-term liabilities	5,720,856	5,644,953
TOTAL LIABILITIES	9,999,022	9,037,447
STOCKHOLDERS' DEFICIT
Common stock, $0.0001 par value, 1,000,000,000 shares authorized 237,649,403 and 192,441,917 shares issued and outstanding, respectively	23,765	19,245
Stock Subscription receivable	(1,000)	(46,000)
Additional paid in capital	64,304,748	59,191,469
Common stock to be issued	0	135,000
Accumulated deficit	(70,282,629)	(64,125,176)
TOTAL STOCKHOLDERS' DEFICIT	(5,955,066)	(4,825,412)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	4,043,956	4,212,035
Convertible Preferred Stock Series C [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	50	50
Convertible Preferred Stock Series B [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Unamortized debt discount	$ 1,790,886	$ 1,583,435
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares, issued	237,649,403	192,441,917
Common stock, shares, outstanding	237,649,403	192,441,917
Convertible note payable
Accrued interest	$ 70,061	$ 274,442
Unamortized debt discount	1,557,786	1,583,435
Convertible Note Payable - Related Party
Accrued interest	6,861
Unamortized debt discount	233,099
Convertible Note Payable Related Parties [Member]
Accrued interest	$ 105,000	$ 261,537
Series C Convertible Preferred Stock [Member]
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock, shares designated	500,000	500,000
Preferred stock, shares issued	500,000	500,000
Preferred stock, shares outstanding	500,000	500,000
Series B Convertible Preferred Stock
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock, shares designated	500,000	500,000
Preferred stock, shares issued	500,000	500,000
Preferred stock, shares outstanding	0	0

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenues	$ 9,581	$ 1,314	$ 26,659	$ 1,314
Operating Expenses:
Research and development expenses	34,713	29,722	89,123	109,086
Selling, general and administrative	456,648	1,182,768	1,614,171	3,083,349
Depreciation and amortization	106,755	106,744	320,264	319,286
Total operating expenses	598,116	1,319,234	2,023,558	3,511,721
Loss from operations	(588,535)	(1,317,920)	(1,996,899)	(3,510,407)
Other (income) expenses:
Interest income	0	0	0	(256)
Change in fair value of derivative liability	(609,053)	500,887	84,462	(418,769)
Derivative liability insufficient shares	(432,350)	0	3,238,429	0
Amortization of debt discount	49,820	46,441	126,472	132,521
Loss (Gain) on extinguishment of debt	9,920	111,818	(162,811)	490,641
Interest expense	64,658	57,481	874,002	1,629,355
Total other (income) expenses	(917,005)	716,627	4,160,554	1,833,492
Loss before provision of income tax	328,470	(2,034,547)	(6,157,453)	(5,343,899)
Provision for income tax	0	0	0	0
NET INCOME (LOSS)	328,470	(2,034,547)	(6,157,453)	(5,343,899)
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ 328,470	$ (2,034,547)	$ (6,157,453)	$ (5,343,899)
Income (Loss) per share
Basic	$ 0.001	$ (0.012)	$ (0.027)	$ (0.034)
Diluted	$ 0.0007	$ (0.012)	$ (0.027)	$ (0.034)
Weighted average common shares outstanding - basic	232,361,241	171,893,796	224,098,382	158,091,581
Weighted average common shares outstanding - diluted	478,507,054

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Total	Common Stock	Common stock to be issued	Additional Paid-In Capital	Subscription receivable	Retained Earnings (Accumulated Deficit)	Convertibles Preferred Stock Series C
Balance, shares at Dec. 31, 2021		138,099,981					500,000
Balance, amount at Dec. 31, 2021	$ (2,338,200)	$ 13,811	$ 4,530,000	$ 51,000,166	$ 0	$ (57,882,227)	$ 50
Common stock issued under s-1, shares		4,000,000
Common stock issued under s-1, amount	594,870	$ 400		594,470
Common stock issued against common stock to be issued purchase of atd, shares		7,000,000
Common stock issued against common stock to be issued purchase of atd, amount	0	$ 700	(4,270,000)	4,269,300
Common stock issued against common stock to be issued received in PY, shares		166,667
Common stock issued against common stock to be issued received in PY, amount	0	$ 17	(25,000)	24,983
Common stock issued stock purchase agreements, shares		976,870
Common stock issued stock purchase agreements, amount	105,000	$ 98		104,902
Common stock issued for services, shares		802,115
Common stock issued for services, amount	79,500	$ 80	100,000	179,420
Cashless exercise stock options, shares		282,759
Cashless exercise stock options, amount	0	$ 28		(28)
Stock issued on settlement of debt, shares		173,390
Stock issued on settlement of debt, amount	32,944	$ 17		32,927
Stock based compensation - stock options	188,917			188,917
Net loss	(2,086,714)					(2,086,714)
Balance, shares at Mar. 31, 2022		151,501,782					500,000
Balance, amount at Mar. 31, 2022	(3,423,683)	$ 15,151	135,000	56,395,057		(59,968,941)
Balance, shares at Dec. 31, 2021		138,099,981					500,000
Balance, amount at Dec. 31, 2021	(2,338,200)	$ 13,811	4,530,000	51,000,166	0	(57,882,227)	$ 50
Net loss	(5,343,899)
Balance, shares at Sep. 30, 2022		185,441,917					500,000
Balance, amount at Sep. 30, 2022	(4,380,386)	$ 18,545	135,000	58,752,209	(60,064)	(63,226,126)	$ 50
Balance, shares at Mar. 31, 2022		151,501,782					500,000
Balance, amount at Mar. 31, 2022	(3,423,683)	$ 15,151	135,000	56,395,057		(59,968,941)
Common stock issued under s-1, shares		6,750,000
Common stock issued under s-1, amount	286,385	$ 675		377,950	(92,240)
Stock issued on settlement of debt, shares		891,610
Stock issued on settlement of debt, amount	64,196	$ 89		64,107
Stock based compensation - stock options	182,215			182,215
Net loss	(1,222,638)					(1,222,638)
stock issued settlement of claim, shares		3,544,247
stock issued settlement of claim, amount	226,171	$ 354		225,817
benficial conversion refinance of debt	154,292			154,292
Balance, shares at Jun. 30, 2022		162,687,639					500,000
Balance, amount at Jun. 30, 2022	(3,733,062)	$ 16,269	135,000	57,399,438	(92,240)	(61,191,579)	$ 50
Common stock issued under s-1, shares		3,227,638
Common stock issued under s-1, amount	171,167	$ 323		138,668	32,176
Stock based compensation - stock options	517,180			517,180
Net loss	(2,034,547)					(2,034,547)
Stock issued in settlement of debt, shares		5,665,636
Stock issued in settlement of debt, amount	348,876	$ 567		348,309
Common stock issuedstock purchase agreements, shares		13,861,004
Common stock issuedstock purchase agreements, amount	350,000	$ 1,386		348,614
Balance, shares at Sep. 30, 2022		185,441,917					500,000
Balance, amount at Sep. 30, 2022	(4,380,386)	$ 18,545	135,000	58,752,209	(60,064)	(63,226,126)	$ 50
Balance, shares at Dec. 31, 2022		192,441,917					500,000
Balance, amount at Dec. 31, 2022	(4,825,412)	$ 19,245	135,000	59,191,469	(46,000)	(64,125,176)	$ 50
Common stock issued under s-1, shares		8,000,000
Common stock issued under s-1, amount	175,000	$ 800		169,200	5,000
Stock based compensation - stock options	103,822			103,822
Net loss	(2,762,628)					(2,762,628)
benficial conversion refinance of debt	575,000
Common stock issued against common stock to be issued, shares		1,000,000
Common stock issued against common stock to be issued, amount	0	$ 100	(135,000)	134,900
Shares issued extinguishment of debt Beneficial conversion payment of interest, shares		22,207,486
Shares issued extinguishment of debt Beneficial conversion payment of interest, amount	688,432	$ 2,220		686,212
Debt modifications / conversions	459,522			459,522
Balance, shares at Mar. 31, 2023		223,649,403					500,000
Balance, amount at Mar. 31, 2023	(6,161,264)	$ 22,365	0	60,745,125	(41,000)	(66,887,804)	$ 50
Balance, shares at Dec. 31, 2022		192,441,917					500,000
Balance, amount at Dec. 31, 2022	(4,825,412)	$ 19,245	135,000	59,191,469	(46,000)	(64,125,176)	$ 50
Net loss	(6,157,453)
Balance, shares at Sep. 30, 2023		237,649,403					500,000
Balance, amount at Sep. 30, 2023	(5,955,066)	$ 23,765	0	64,304,748	(1,000)	(70,282,629)	$ 50
Balance, shares at Mar. 31, 2023		223,649,403					500,000
Balance, amount at Mar. 31, 2023	(6,161,264)	$ 22,365	0	60,745,125	(41,000)	(66,887,804)	$ 50
Common stock issued under s-1, shares		4,000,000
Common stock issued under s-1, amount	112,550	$ 400		72,150	40,000
Stock based compensation - stock options	21,404			21,404
Net loss	(3,723,295)					(3,723,295)
Balance, shares at Jun. 30, 2023		227,649,403					500,000
Balance, amount at Jun. 30, 2023	(9,750,605)	$ 22,765	0	60,838,679	(1,000)	(70,611,099)	$ 50
Common stock issued under s-1, shares		10,000,000
Common stock issued under s-1, amount	190,225	$ 1,000		189,225
Stock based compensation - stock options	38,415			38,415
Net loss	328,470					328,470
Satisfaction of Short Share liability	3,238,429			3,238,429
Balance, shares at Sep. 30, 2023		237,649,403					500,000
Balance, amount at Sep. 30, 2023	$ (5,955,066)	$ 23,765	$ 0	$ 64,304,748	$ (1,000)	$ (70,282,629)	$ 50

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,157,453)	$ (5,343,899)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation	24,429	23,451
Derivative Liability insufficient Shares	3,238,429	0
Stock based compensation	163,641	888,313
Amortization of prepaid insurance/expense	42,858	187,562
Amortization of debt discount	126,471	132,521
amortization of deferred rent	(519)	0
Common stock issued for services	0	79,500
Common stock issued in settlement of an obligation	0	230,369
loss on conversion of convertible note	0	122,887
Amortization of intangible assets	295,836	295,834
Loss (gain) on extinguishment of debt	(162,811)	137,388
Change in fair value of derivative liability	84,462	(418,769)
Non-cash interest expense	690,000	1,316,846
Proceeds from convertible notes	0	102,387
Changes in operating assets & liabilities:
(Increase) decrease in other assets	6,811	0
Increase in shareholder advances	32,450	1,701
(Increase) decrease in prepaid expenses	0	(89,391)
Increase in due to first insurance funding	0	80,614
Increase in deferred revenue inventory	0	148,685
Decrease in deferred revenue	(22,437)	0
Increase (decrease) in accounts payable and accrued expenses	587,777	375,180
Net cash provided by (used in) operating activities from operations	(1,050,056)	(1,728,821)
CASH FLOW FROM INVESTING ACTIVITIES:
Purchase of property and equipment	0	(8,710)
Net cash provided by (used in) investing activities	0	(8,710)
CASH FLOW FROM FINANCING ACTIVITIES:
Common stock issued under registration statement on Form S-1	477,775	1,052,419
Common stock issued under SPA	0	455,000
Repayment of first insurance funding	26,781	59,789
Proceeds from convertible notes	575,000	1,325,000
Repayment of convertible notes	0	(1,243,200)
Repayment of promissory note	0	(81,116)
Net cash provided by (used in) financing activities	1,025,994	1,448,314
Net (decrease) increase in cash and cash equivalents	(24,062)	(289,217)
Cash and cash equivalents at beginning of period	47,282	452,963
Cash and cash equivalents at end of period	23,220	163,746
CASH PAID DURING THE PERIOD FOR:
Interest	0	142,500
Income taxes - net of tax refund	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Common stock issued against common stock to be issued	135,000	125,000
Common stock issued for severance	0	64,197
Initial derivative liability at issuance of notes	1,265,000	2,641,846
Initial debt discount at issuance of notes	$ 250,000	$ 1,325,000
Convertible note converted to common stock	688,432	32,944
Convertible note issued against settlement of liabilities	$ 250,000	$ 348,876
Initial debt discount on extinguishment of notes	209,522	0
Common stock issued against stock subscription receivable	40,000	60,064
Promissory note refinanced against convertible note		367,931
Common stock issued on cashless exercise of options		28
Common stock issued against Common stock to be issued for acquisition		4,270,000
Reversal of derivative liability on short shares	$ 3,238,430	$ 0

ORGANIZATION

ORGANIZATION	9 Months Ended
	Sep. 30, 2023
ORGANIZATION
ORGANIZATION	NOTE 1: ORGANIZATION The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc. On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations. The Company’s principal executive office is located at 6191 Cornerstone Court E suite 114 San Diego Ca 92121. On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc. This subsidiary will be used to help facilitate the anticipated activities planned by the Company. On May 11, 2015 the Company acquired a 100% interest in CanChew License Company a Nevada incorporated licensing Company, through the exchange of 5,826,706 shares of its common stock. In October 2017 the company formed a wholly owned subsidiary in the Netherlands for purposes of holding pharmaceutical licenses as required by the Netherlands regulations and laws. On October 16, 2018, the Company formed a wholly owned disregarded entity Marina Street, LLC as part of improvement of internal control over cash management and bank activities. On March 17, 2020, the Company acquired Sapphire Biotech, Inc., (“Sapphire’) which is research and Development Company that has a mission to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis. Sapphire is also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. Additionally, with the onset of the COVID-19 pandemic, the Company decided to begin creating COVID-19 rapid diagnostic tools, including multiple first-in-class COVID-19 neutralizing antibody tests and other innovations. Sapphire’s operations are located in the Greater San Diego Area. COVID-19 impact and related risks The ongoing global outbreak of COVID-19, and the various attempts throughout the world to contain it, have created significant volatility, uncertainty and disruption. In response to government directives and guidelines, health care advisories and employee and other concerns, A number of the Company’s employees have had to work remotely from home and those on site have had to follow the Company’s social distance guidelines, which could impact their productivity. COVID-19 could also disrupt the Company’s operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who cannot effectively work remotely but who elect not to come to work due to the illness affecting others in the Company’s office or laboratory facilities, or due to quarantines. Because of COVID-19, travel, visits, and in-person meetings related to The Company’s business have been severely curtailed or cancelled and the Company has instead used on-line or virtual meetings to meet with potential customers and others. In addition to operational adjustments, the consequences of the COVID-19 pandemic have led to uncertainties related to The Company’s business growth and ability to forecast the demand for its diagnostic testing and resulting revenues. The full extent to which the COVID-19 pandemic and the various responses to it might impact The Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond The Company’s control. Russia-Ukraine/ Israel Hamas conflicts The ongoing conflicts in these areas has not currently had a direct impact on the company’s operations. Because of these conflicts, any potential travel, visits, and in-person meetings related to The Company’s business have been severely curtailed or cancelled and the Company has instead used on-line or virtual meetings to meet with potential customers and others. In addition to possible operational adjustments, the consequences of these conflicts may lead to uncertainties related to The Company’s business growth and ability to forecast the demand for its diagnostic testing and resulting revenues. The full extent to which these conflicts and the various responses to it might impact The Company’s business, operations and financial results will depend on numerous evolving factors that are not subject to accurate prediction and that are beyond The Company’s control. Changes to the Company’s Board of Directors On January 4, 2022, Mauricio Gatto Bellora tendered his resignation as a member of the Company’s Board of Directors, and the Company on that date accepted his resignation. Mr. Bellora’s decision to resign was not the result of any disagreement with the Company. On January 6, 2022, the record holder of 500,000 shares of the Company’s Series C Preferred Stock, representing 100% of the 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are entitled to cast a vote for election of up to four Series C Directors, whether by shareholder meeting (annual or special) or by written consent, acting pursuant to Section 78.320 of the Nevada Revised Statutes and Article III, Section 3 of the Company’s Amended and Restated Bylaws, consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto Bellora. Mr. Blake N. Schroeder, 42, began his career with a commercial litigation law firm in Salt Lake City, Utah. Beginning in 2008, Schroeder focused on the sale and marketing of natural products and opening international marketplaces to those products. From 2008 to 2014 Mr. Schroeder served in various capacities at MonaVie, LLC developing international business plans and growing international businesses. From August 2014 to February 2016, Mr. Schroeder served as the Chief Operating Officer of For evergreen International, where he was responsible for global operation and sales of the multinational organization, including oversight of a global supply chain. From 2021 to the present, Mr. Schroeder has served as the Chief Executive Officer and Chairman of the Board of Medical Marijuana, Inc. From 2016 to the present, Mr. Schroeder serves as the chief executive officer of Kannaway USA, LLC, a wholly owned subsidiary of Medical Marijuana, Inc. Medical Marijuana, Inc. is one of the Company’s largest shareholders holding approximately 16.4% of the Company’s common stock, as of January 10, 2022. Mr. Schroeder holds a B.S. in Finance from Utah State University and a law degree from Syracuse University College of Law. Changes in the Business On March 7, 2022, the Company announced that is has shifted its focus for its rapid COVID-19 Neutralizing Antibody (“Nab”)(NAb) Test to become For Research Use Only (“RUO”). The test will provide researchers an important tool for COVID-19 research and is not intended for use in diagnostic procedures. The Company has also entered a separation agreement with Empowered Diagnostics, LLC following the FDA recall of Empowered’s products, including the NabNAb test.

ACQUISITION OF INTELLECTUAL PRO

ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC LLC	9 Months Ended
	Sep. 30, 2023
ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC LLC
ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC.	NOTE 2: ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC, LLC. AXIM entered into two substantially contemporaneous transactions to acquire patents and 510(K) Licenses from Advanced Tear Diagnostics, LLC (the “Seller”) (collectively, the “Asset Acquisition”) for a total amount of $4,520,000. The first transaction occurred on July 29, 2021, in which AXIM purchased five patents (the “Patents”) from the Seller for $250,000 (which includes assuming and paying $30,000 of the Seller’s liabilities). The bulk of the purchase price ($210,000) was in a note that requires seven equal monthly payments of $30,000, which payment started on September 3, 2021. The second transaction occurred on August 26, 2021, in which AXIM purchased certain eye disease diagnostic technology, which consisted of a 510(K) license for Lactoferrin, a biomarker for dry eye disease and a 510(K) license for IgE, a biomarker for allergic ocular reaction (collectively, the “510(K) Licenses”). The purchase price for the 510(K) Licenses was $4,270,000, which price was paid by issuing to the Seller 7 million shares of AXIM restricted common stock. Together, the Patents and the 510(K) Licenses constitute the acquired technology asset (the “Technology Asset”), which for accounting purposes, are considered one unit of account. We are amortizing the Technology Asset ratably over the 11.54 average remaining life of the Patents. In accordance with FASB’s requirements for accounting for business combinations (FASB Accounting Standards Codification, Topic 805, Business Combinations

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2023
BASIS OF PRESENTATION
BASIS OF PRESENTATION	NOTE 3: BASIS OF PRESENTATION: The interim unaudited condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading. The condensed balance sheet information as of December 31, 2022 was derived from the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2022 (“2022 Annual Report”), filed with the SEC pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on April 17, 2023. These interim unaudited condensed financial statements should be read in conjunction with the 2022 Annual Report. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period. Principles of Consolidation The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiaries Axim Holdings, Inc., Marina Street LLC, Axim Biotechnologies (the Netherland Company) and Sapphire Biotech, Inc. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated upon consolidation.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2023
GOING CONCERN
GOING CONCERN	NOTE 4: GOING CONCERN The Company’s consolidated financial statements have been presented assuming that the Company will continue as a going concern. As shown in the consolidated financial statements, the Company has negative working capital of $4,254,946 and has an accumulated deficit of $70,282,629, has cash used in operating activities $1,050,056. The Company extinguished its old debt and entered in debt exchange agreement. On April 16, 2018, the Company entered into a Stock Purchase Agreement and sold 1,945,000 shares of our common stock registered under the Registration Statement on Form S-3 declared effective by the Securities and Exchange Commission on September 14, 2017. On March 11, 2019 the company issued shares in accordance with an SPA dated August 1, 2018 which the amount reduced due to shareholder by $400,000. During the nine months ended September 30, 2023, the Company raised additional capital of $477,775 through its S-1. This capital provides funds for research, development, and ongoing operations. The Company intends to raise substantial additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. That will raise a doubt about the ability of the Company to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2023
BASIS OF PRESENTATION
SIGNIFICANT ACCOUNTING POLICIES	NOTE 5: SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Significant estimates are estimates of discount rates in lease, assumptions about collection of useful life of intangible assets and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate. Operating lease We lease property under various operating leases which are disclosed on our consolidated Balance sheet in accordance with ASC 842. Risks and uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Form 10-K. Cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of September 30, 2023, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at September 30, 2023 and December 31, 2022. The Company has never experienced any losses related to these balances. Accounts Receivable It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers. Concentrations At September 30, 2023 and December 31, 2022, there were no accounts receivable. For the three and nine months ended September 30, 2023 one customer accounted for 100% of total revenue. For the three and nine months ending September 30, 2022 one customer accounted for 100% of total revenue. Property and equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. The Company’s property and equipment consisted of the following at September 30, 2023 and December 31, 2022, respectively. September 30, 2023 December 31, 2022 Equipment $ 183,992 $ 183,992 Less: accumulated depreciation $ 114,582 $ 90,152 $ 69,410 $ 93,840 Depreciation expense was $8,143, $24,429 and $8,143, $23,451 for the three and nine months ended September 30, 2023 and 2022, respectively. Intangible Assets Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct an impairment analysis for goodwill annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if we elect to bypass the qualitative assessment, goodwill is tested using a quantitative impairment test. Impairment of Indefinite-Lived Intangible Assets For indefinite-lived intangible assets such as in-process research and development (IPRD), we conduct an impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist. We first perform a qualitative assessment to determine if it is more likely than not that the carrying amount of each of the in-process research and development assets exceeds its fair value. The qualitative assessment requires the consideration of factors such as recent market transactions, macroeconomic conditions, and changes in projected future cash flows. If we determine it is more likely than not that the fair value is less than its carrying amount of the in-process research and development assets, a quantitative assessment is performed. The quantitative assessment compares the fair value of the in-process research and development assets to its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized for the excess. We elected to perform a quantitative assessment of indefinite-lived intangible assets and determined that the fair value of the goodwill and IPRD related to the Sapphire acquisition was less than its carrying amount and that in-process research and development were fully impaired. The Company’s intangible assets consisted of the following at September 30, 2023 and December 31, 2022, respectively. September 30, December 31, 2023 2022 Patents $ 250,000 $ 250,000 Licenses 4,270,000 4,270,000 4,520,000 4,520,000 Less: accumulated amortization 826,407 530,573 $ 3,693,593 $ 3,989,427 Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows: 2023 2024 2025 2026 2027 2028 and thereafter Amortization expense $ 97,405 $ 389,123 $ 389,123 $ 389,123 $ 389,123 $ 2,039,696 Amortization expense recorded for the three and nine months ended September 30, 2023 and 2022 was $98,612, $98,612 and $295,836, $295,836 respectively. Revenue Recognition The Company follows the guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. All revenue was from operations that were divested. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from operations recognized for three and nine months ended September 30, 2023 and 2022 amounted to $9,581, $1,314 and $26,659, $1,314 respectively. Fair Value Measurements The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The Company’s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, notes payable, and long-term debt. The recorded values of cash and cash equivalents and accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and long-term debt approximate their fair values, as interest approximates market rates. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The Company recognizes its derivative liabilities as Level 3 and values its derivatives using the methods discussed below. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed are that of volatility and market price of the underlying common stock of the Company. Items recorded or measured at fair value on a recurring basis in the accompanying condensed consolidated financial statements consisted of the following items as of September 30, 2023. Total Level 1 Level 2 Level 3 Derivative liabilities $ 2,373,804 $ - $ - $ 2,373,804 December 31, 2022 Total Level 1 Level 2 Level 3 Derivative liabilities $ 1,648,831 $ - $ - $ 1,648,831 Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities.” Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability. Income Taxes The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. No amounts were accrued for the payment of interest and penalties as of September 30, 2023 and December 31, 2022 respectively. The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the Nine months ended September 30, 2023 and 2022 respectively. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “Cares Act”) was enacted. The CARES Act included loans and grants to certain businesses, and temporary amendments to the Internal Revenue Code which changed net loss carryforward and back provisions and the business interest expenses limitation. Under the CARES Act provisions, the most relevant income tax considerations to Oncocyte relate to the amounts received under the Paycheck Protection Program loan program and the possible forgiveness of those loans by the SBA. On December 21, 2020, the U.S. president has signed into law the “Consolidated Appropriations Act, 2021” which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds for federal tax purposes. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company had $0 and $0 allowance for doubtful accounts at September 30, 2023 and 2022, respectively and had $0 accounts receivable at September 30, 2023 and $0 at December 31, 2022. Net Loss per Common Share Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were common share equivalents 254,739,838 at September 30, 2023 and 47,298,693 at December 31, 2022. For the Period ended September 30, 2023 these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. If necessary, the company would increase authorized shares to honour conversion agreements. The company recognized a derivative short share expense for the three and nine months ending September 30, 2023 in the amounts of $(432,350) and $3238,429 respectively as a result of authorized shares being insufficient to redeem convertible securities and notes. This was resolved in Quarter ending September 30, 2023. During the Quarter ended September 30, 2023, the Company increased the authorized capital from 300,000,000 to 1,000,000,000 shares and therefore there is sufficient authorized capital as of September 30, 2023, results into no short share derivative liability accrual needed and so reclass the same to additional paid in capital as per ASC 815. Stock Based Compensation All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the Black-Scholes option pricing model in accordance with ASC 505-50, Equity-Based Payment to Non-employees Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the three and nine months ended September 30, 2023 and 2022 the Company incurred research and development expenses of $34,713, $29,722 and $89,123, $109,086, respectively. The Company has entered into various agreements with CROs. The Company’s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Material Equity Instruments The Company evaluates stock options, stock warrants and other contracts (convertible promissory note payable) to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for under the relevant sections of ASC 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity (“ASC 815”). Certain of the Company’s embedded conversion features on debt and outstanding warrants are treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 840-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1)earliest issuance date or (2) latest maturity date. In the case of insufficient authorized share capital available to fully settle outstanding contracts, the Company utilizes the earliest maturity date sequencing method to reclassify outstanding contracts as derivative instruments. These contracts are recognized currently in earnings until such time as the convertible notes or warrants are exercised, expire, the related rights have been waived and/or the authorized share capital has been amended to accommodate settlement of these contracts. These instruments do not trade in an active securities market. Recently Issued Accounting Standards Accounting Standards Implemented Since December 31, 2022 ASC Update 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this Update do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic. That is, accounting for those instruments continues to be subject to the requirements in other Topics. The amendments in this Update do not affect a holder’s accounting for freestanding call options. ASC Update No. 2020-10 In October 2020, the FASB issued ASC Update No. 2020-10, Codification Improvements. Update No. 2020-10 amends a wide variety of Topics in the Codification in order to improve the consistency of the Codification and the application thereof, while leaving Generally Accepted Accounting Principles unchanged. ASC Update No. 2020-06 In August 2020, the FASB issued ASC Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in Update No. 2020-06 simplify the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity’s own equity. Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

PREPAID EXPENSES

PREPAID EXPENSES	9 Months Ended
	Sep. 30, 2023
PREPAID EXPENSES
PREPAID EXPENSES	NOTE 6: PREPAID EXPENSES Prepaid expenses consist of the following as of September 30, 2023 and December 31, 2022 respectively: September 30, December 31, 2023 2022 Prepaid insurance $ - $ 42,078 Prepaid interest - 780 $ - $ 42,858 For the three and nine months ended September 30, 2023 and 2022 the Company recognized amortization of prepaid expense and prepaid insurance of $-0- $22,121 and $42,858, $187,562 respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2023
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 7: RELATED PARTY TRANSACTIONS Related Party The Company has an employment agreement with Catalina Valencia at a rate of $15,000 per month commencing March 17, 2020. The agreement can be terminated with 30 days’ notice by either party. The company has a consulting agreement with Glycodots LLC whereby it will provide the services of Dr. Sergei A. Svarovsky at a rate of $15,000 per month commencing March 17, 2020. The agreement can be terminated with 30 days’ notice by either party. Purchase of Promissory Note and Forbearance Agreement Effective May 4, 2020, the Company acquired from TL-66, a California limited liability company (“Seller”), a promissory note issued to Seller by Dr. Anastassov (“Maker”) dated December 1, 2017, with a face value of $350,000 and a remaining balance due of approximately $100,000 (the “Note”). The purchase price for the Note was $100,000 payable by the Company issuing Seller One Million (1,000,000) restricted shares of the Company’s Common Stock. Effective May 6, 2020, the Company and Maker entered into a Forbearance Agreement whereby the Company agreed to forbear from making any collection efforts on the Note for a period of 24 months so long as Maker has not breached the Separation Agreement. Following 24 months, if there has been no breach of the Separation Agreement by Maker, repayment of the Note, including all principal and unpaid interest, will be waived in full. As of May, 4, 2020 the carrying value of the note receivable was $102,567, the value of the common stock to be issued was $135,000, resulting in a loss of $32,433 accounted as loss on debt extinguishment. The balance of the Note Receivable as of September 30, 2023 and December 31, 2022 is $0 and $0 excluding interest accrued thereon of $0 and $0, respectively. The note was forgiven in May, 2022.

DUE TO FIRST INSURANCE FUNDING

DUE TO FIRST INSURANCE FUNDING	9 Months Ended
	Sep. 30, 2023
DUE TO FIRST INSURANCE FUNDING
DUE TO FIRST INSURANCE FUNDING	NOTE 8: DUE TO FIRST INSURANCE FUNDING On June 25, 2022, the Company renewed its D&O insurance policy with total premiums, taxes and fees for $87,762. A cash down payment of $8,776 was paid on July 6, 2022. Under the terms of the insurance financing, payments of $8,957, which include interest at the rate of 4.92% per annum, are due each month for nine months commencing on July 25, 2022. The total outstanding due to First Insurance Funding as of September 30, 2023 and December 31, 2022 is $-0- and $26,781, respectively. The policy was cancelled for non-payment of premium in April 2023.

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2023
CONVERTIBLE NOTES PAYABLE
CONVERTIBLE NOTES PAYABLE	NOTE 9: CONVERTIBLE NOTES PAYABLE The following table summarizes convertible note payable of related party as of September 30, 2023 and December 31, 2022 respectively: September 30, December 31, 2023 2022 Convertible note payable, due on November 1, 2026, interest at 3.5% p.a. $ 4,000,000 $ 4,000,000 Accrued interest 105,000 261,537 Convertible note payable, net $ 4,105,000 $ 4,261,537 On January 23, 2023, Creditor agreed to waive and forfeit all interest accrued on the MMI Note through December 31, 2022, in the aggregate amount of $261,537, and to waive all prior defaults on the MMI Note through the Effective Date. Interest shall accrue on the MMI Note at the original rate of 3.5% per annum through September 30, 2023, and be payable on that date. Thereafter interest will be payable on a monthly basis beginning on August 1, 2023. In addition, the Conversion Price for the MMI Note is hereby reduced from $0.25 to $0.075. This Agreement serves to modify and amend the MMI Note as set forth herein, in all other respects the terms of the MMI Note remain in full force and effect. The Company determined that the debt modification including conversion feature added resulted in a debt extinguishment due to the change in the fair values exceeding 10% of the debt carrying value. As a result of the debt modification the company recorded a gain on Extinguishment of debt in the amount of $261,537. For the three and nine months ended September 30, 2023 and 2022, interest expense was $35,000, $35,000 and $105,000, $105,000, respectively. As of September 30, 2023 and December 31, 2022, the balance of secured convertible note was $4,105,000 and $4,261,537 which included $105,000 and $261,537 accrued interest, respectively. The following table summarizes convertible note payable as of September 30, 2023 and December 31, 2022 respectively: September 30, December 31, 2023 2022 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. (1) $ 484,478 $ 484,478 Convertible Note Payable, due on January 27,2032 interest at 3% p.a. (4) 367,931 367,931 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. (2) 500,000 500,000 Convertible note payable, due on February 10, 2032, interest at 3.0% p. a. (5) 800,000 1,150,000 Convertible note payable, due on December 31, 2034, interest at 3% p.a. (3) 190,000 190,000 Convertible note payable, due on May 23, 2033, interest at 3.75% p.a. 250,000 - Convertible note payable, due on May 23, 2033, interest at 3.75% p.a. 325,000 - Accrued interest (The accrued interest and principal are both included in the captions titled “convertible note payable” in the balance sheet) 70,061 274,442 Total 2,987,470 2,966,851 Less: unamortized debt discount/finance premium costs (1,557,786 ) (1,583,435 ) Convertible note payable, net $ 1,429,684 $ 1,383,416 (1) On September 16, 2016, we entered into a convertible note purchase agreement (the “Convertible Note Purchase Agreement” or “Agreement”) with a third-party investor. Under the terms of the Convertible Note Purchase Agreement the investor may acquire up to $5,000,000 of convertible notes from the Company. With various closings, under terms acceptable to the Company and the investor as of the time of each closing. Pursuant to the Agreement, on September 16, 2016 the investor provided the Company with $850,000 secured convertible note financing pursuant to four (4) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes matures on October 1, 2029, and pay 3.5% compounded interest paid bi-annually. The Note are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company common stock at a conversion price equal to $0.2201 per share. As of September 30, 2023 and December 31, 2022 respectively, the balance of secured convertible notes was $497,748 and $590,945, which included $13,000 and $106,467 accrued interest, respectively. See below for debt modification treatment. (2) On October 20, 2016, a third-party investor provided the Company with $1,000,000 secured convertible note financing pursuant to three (3) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes mature on October 1, 2029 and pay 3.5% compounded interest paid bi-annually. The Notes are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company’s common stock at a fixed conversion price equal of $0.2201 per share. The investor paid cash of $500,000 for one of the Notes and issued to the Company two (2) secured promissory notes of $250,000 each for two (2) Convertible Notes of $250,000 each. The two secured promissory notes issued by the investor (totalling $500,000) as payment for two (2) secured Notes totalling $500,000 mature on February 1, 2017 ($250,000) and March 1, 2017 ($250,000), bear interest at the rate of 1% per annum, are full recourse and additionally secured by 10,486,303 shares of Medical Marijuana, Inc. (Pink Sheets symbol: MJNA) and were valued at $858,828 based upon the closing price of MJNA on October 20, 2016. A debt discount was recorded related to beneficial conversion feature inn connection with this convertible note of $499,318, related to the beneficial conversion feature of the note to be amortized over the life of the note or until the note is converted or repaid. As of September 30, 2023 and December 31, 2022 respectively, this note has not been converted and the balance of secured convertible notes was $513,497 and $610,104, which included $13,497 and $110,104 accrued interest, respectively. See below for debt extinguishment treatment. (1) & (2) On January 23, 2023, Creditor agreed to waive and forfeit all interest accrued on the Secured Notes through December 31, 2022, in the aggregate amount of $216,572. All prior defaults on the Secured Notes are hereby waived through the Effective Date, and the next interest payments due on each of the Secured Notes is extended from April 1, 2023, to July 1, 2023. In addition, the Conversion Price for each of the Secured Notes is hereby reduced from $0.2201 to $0.04. The Agreement served to modify and amend each of the Secured Notes as set forth above, in all other respects the terms of the Secured Notes remained in full force and effect. The Company determined that the debt modification including conversion feature added resulted in a debt extinguishment due to the change in the fair values exceeding 10% of the debt carrying value. The Renegotiation of the above TL-66 notes was deemed to be a debt extinguishment resulting in Amortization of the remaining debt discount of $381,760 and recognition of the Beneficial conversion feature upon modification of $209,522. And a gain on conversion of $35,537 calculated by comparing fair value of new note to old note including accrued interest. On June 7, 2021 the Company converted $500,000 of the Convertible Note with TL-66-LLC along with the accrued interest of $82,707 into 2,647,464 shares of the Company’s common stock at $0.2201 per share which resulted in a loss on extinguishment of debt of $1,535,264. (3) On December 31, 2019, Sapphire Biotech, Inc. entered into a Convertible Note Purchase Agreement whereas the Company issued a convertible note with a face value of $190,000 with a compounding interest rate of 3% per annum, the interest shall be payable annually beginning on December 31, 2020 until the maturity date of December 31, 2034, at which time all principal and interest accrued thereon shall be due and payable. The Convertible Note is secured by substantially all the Company’s tangible and intangible assets. In addition, the Convertible Note includes various non-financial covenants including the Company may not enter into any agreement, arrangement or understanding of any kind that would result in a transaction, or series of transactions, that would result in the sale of 50% or more of the Company’s capital stock without the prior approval of the holder. Upon issuance, the Convertible Note was convertible into shares of the Company’s common stock at $1.90 per share. At December 31, 2019, the Company determined that the Convertible Note contained a beneficial conversion feature for which a full discount was recorded on the Convertible Note. The fair market value of the Company’s common stock was based upon the estimated per share acquisition price per the pending acquisition of the Company. The discount of $190,000 will be amortized using the effective interest method and will be fully amortized by December 31, 2034. On March 17, 2020, the Company entered into a Share Exchange Agreement (“Agreement”) with Sapphire Biotech, Inc., a Delaware corporation (“Sapphire”) and all of the Sapphire stockholders (collectively, the “Sapphire Stockholders”). Following the closing of the transaction, Sapphire will become a wholly owned subsidiary of AXIM. Under the terms of the Agreement, the Company intends to assume the convertible notes in the principal amounts of $190,000. After the acquisition, the Convertible Note was able to convert 6,000,000 shares of Axim’s common stock. Upon assumption of the note, the Company recorded a beneficial conversion feature of $190,000. As of September 30, 2023 and December 31, 2022, the balance of secured convertible note was $194,276 and $207,116, which included $4,276 and $17,116 accrued interest, respectively. On January 27, 2023, Creditor agreed to waive and forfeit all interest accrued on the Sapphire Note through December 31, 2022, in the aggregate amount of $17,115 and to waive all prior defaults on the Sapphire Note through the Effective Date. This was not deemed to be a debt extinguishment since the waiver of accrued interest was not deemed to produce a change in cash flow greater than 10%. The company recorded a gain on modification of $17,117 resulting from forgiveness of accrued interest. (4) On January 27, 2022, Sapphire Bitotech entered into a debt exchange agreement (effective April 1 2022) whereas the company exchanged a convertible note with a balance of 367,931 including accrued interest for a new note charging interest at a rate of 3% per annum first interest payment due January 27, 2023 compounded monthly. The maturity date is January 27, 2032. Upon issuance was convertible into shares of the Company’s common stock at a conversion price of $0.10 per share. As of September 30, 2023 and December 31, 2022, the balance of secured convertible note was $375,300 and $378,193, which included $7,369 and $10,262 accrued interest, respectively. This was not deemed to be a debt extinguishment. On January 23, 2023, Creditor agreed to waive and forfeit all interest accrued on the TL-66 Note through January 27, 2023, in the aggregate amount of $11,190, and to waive all prior defaults on the TL-66 Note through the Effective Date. This was not deemed to be a debt extinguishment since the waiver of accrued interest was not deemed to produce a change in cash flow greater than 10%. The company recorded a gain on modification of $11,190 resulting from forgiveness of accrued interest. Convertible Note payable – related party (officer) As of December 31, 2022, the Company owed to the Executive, for employment in his capacity as CEO of AXIM, $512,500 of unpaid salary which is overdue and payable immediately. Executive and AXIM desired to enter into this Agreement in order resolve the Amount Due in a way that preserves the Company’s working capital and incentivizes and retains Executive. Executive agreed to Issuance of Convertible Note as Partial Satisfaction of the Amount Due. $250,000 of the Amount Due will be paid by issuing to Executive a convertible note, face value $250,000 (the "Convertible Note") Executive agreed that he shall waive/forfeit $50,000 of the Amount Due, leaving a remaining balance after such waiver of $212,500 ($512,500 minus $250,000 for the Convertible Note = $262,500 minus $50,000 waiver = $212,500), which shall not be payable at any time prior to July 1, 2023, and that Executive shall have no right prior to July 1, 2023 to seek payment of the remaining balance of the Amount Due. Executive further agrees that if in the reasonable discretion of the Board of Directors full payment of the remaining balance of the Amount Due on July 1, 2023 ($212,500) is too burdensome for the Company’s working capital position at that time, then Executive will either grant an additional 3-month extension for the payment of the remaining Amount Due or engage in good faith discussions with the Board in order to enter into a payment plan for the remaining Amount Due, or a combination of both. Payment of Principal and Interest. From the date of this Convertible Note (the “Note” or “Convertible Note”), interest shall be payable annually on the basis of a three hundred sixty (360) day year and compounded on a yearly basis at a rate equal to Four Percent (4%) per annum (the “Interest Rate”). beginning on January 23, 2024 until the maturity date of January 23, 2033, at which time all principal and interest accrued thereon shall be due and payable. Upon issuance, the Convertible Note was convertible into shares of the Company’s common stock at $0.01 per share. At January 23, 2023, the modification date, the Company determined that the Convertible Note contained a beneficial conversion feature for which a full discount was recorded on the Convertible Note. The fair market value of the Company’s common stock was based upon the estimated per share acquisition price per the pending acquisition of the Company. The discount of $250,000 will be amortized using the effective interest method and will be fully amortized by January 23, 2033. This is a new note accounted for by recording the note at face value and a debt discount of $250,000 which will be amortized over the life of the note. As of September 30, 2023 and December 31, 2022 the balance due on the note was $256,861 and $-0- including accrued interest of $6,861 and $-0- respectively. (5) Convertible Notes Effective February 10, 2022, the Company issued seven convertible notes to a series of investors having an aggregate face value of $1,325,000 in exchange for $1,325,000 in cash (the “Convertible Notes”). One of the Convertible Notes, face value $25,000, was purchased by Blake N. Schroeder who is a director of the Company. Each of the Convertible Notes is (i) unsecured; (ii) bears interest at a rate of 3% per annum; (iii) matures on February 10, 2032; and (iv) is convertible, in whole or in part, at any time by the holder, into restricted shares of the Company’s common stock at a conversion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Company’s common stock in the ten trading days preceding any particular conversion, provided, the holder is prohibited from converting the convertible note, or portion thereof, if such conversion would result in beneficial ownership by the holder and its affiliates of more than 4.999% of Company’s issued and outstanding common stock as of the date of the conversion. A debt discount was recorded related to beneficial conversion feature in connection with this convertible note of $1,325,000, which to be amortized over the life of the note or until the note is converted or repaid. During the year ended December 31, 2022, $175,000 of the note and accrued interest of $2,840 was retired and converted to 5,665,636 common shares valued at $349,535 and as a result recognized a loss on extinguishment of $111,807, including cancellation of balance debt discount of $167,571 and a gain due to cancellation of derivative liabilities as of date of settlement of $227,459 During the nine months ended September 30, 2023, $350,000 of the note and accrued interest of $30,858 was retired and converted to 22,207,486 common shares valued at $688,432 and as a result of the debt modification the company recognized a loss on extinguishment of $626,414, including cancellation of balance debt discount of $318,840 and a loss on issuance of the shares of $307,574 and a gain due to cancellation of derivative liabilities as of date of settlement of $624,490. As of September 30, 2023 and December 31, 2022, respectively, the principal and accrued interest balances were $824,361 and $1,180,492 respectively, which include accrued interest of $24,361 and $30,492, respectively. During the three and nine months ended September 30, 2023 and 2022 respectively, the Company amortized the debt discount on all the notes of $49,820, $46,441 and $126,472, $132,521, respectively. As of September 30, 2023 and December 31, 2022, unamortized debt discount was $1,790,886 and $1,583,435, respectively. Effective May 23, 2023, the Company issued 5 convertible notes to a series of investors having an aggregate face value of $575,000 in exchange for $575,000 in cash. Each of the Convertible Notes is (i) unsecured; (ii) bears interest at a rate of 3.75% per annum; (iii) matures on May 23, 2033; and (iv) is convertible, in whole or in part, at any time by the holder, into restricted shares of the Company’s common stock at a conversion price equal to the lesser of $0.01 or 70% of the average of the two lowest closing prices of the Company’s common stock in the ten trading days preceding any particular conversion, provided, the holder is prohibited from converting the convertible note, or portion thereof, if such conversion would result in beneficial ownership by the holder and its affiliates of more than 4.999% of Company’s issued and outstanding common stock as of the date of the conversion. A debt discount was recorded related to beneficial conversion feature in connection with this convertible note of $575,000, which to be amortized over the life of the note or until the note is converted or repaid. Debt Obligations - 2022 Effective February 10, 2022, The Company issued the following debt obligations in exchange for cash. A portion of the funds received by the Company were used to pay off the GS Capital Partners, LLC note, as discussed below. Short Term Promissory Notes Effective February 10, 2022, the Company issued two short term notes, each having a face amount of $250,000, in exchange for a total of $500,000 in cash (the “Short Term Promissory Notes”). The Short Term Promissory Notes bear interest at the rate of 1.5% per annum and were due and payable on or before March 10, 2022, unless demand for payment is made prior to such date. Both the notes were paid in full in February 2022.

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2023
BASIS OF PRESENTATION
DERIVATIVE LIABILITIES	NOTE 10: DERIVATIVE LIABILITIES Upon the issuance of certain convertible note payable having a variable conversion rate, the Company determined that the features associated with the embedded conversion option embedded in the debt, should be accounted for at fair value, as a derivative liability. We have determined that certain convertible debt instruments outstanding as of the date of these financial statements include an exercise price “reset” adjustment that qualifies as derivative financial instruments under the provisions of ASC 815-40, Derivatives and Hedging - Contracts in an Entity’s Own Stock (“ASC 815-40”). Certain of the convertible debentures have a variable exercise price, thus are convertible into an indeterminate number of shares for which we cannot determine if we have sufficient authorized shares to settle the transaction with. Accordingly, the embedded conversion option is a derivative liability and is marked to market through earnings at the end of each reporting period. Any change in fair value during the period recorded in earnings as “Other income (expense) - gain (loss) on change in derivative liabilities.” On February 10, 2022 i.e. on the date of issuance of derivative instrument, the Company estimated the fair value of the embedded derivatives of $2,641,846 using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 163.09%, (3) risk-free interest rate of 2.03%, and (4) expected life of 10 years. The value of notes $1,325,000 was debited to beneficial conversion feature and the balance $1,316,846 was recorded as non-cash interest expenses under interest expenses in statement of operation. On September 30, 2023, the Company estimated the fair value of the embedded derivatives of $2,982,856 using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 158.74%, (3) risk-free interest rate of 3.88%, and (4) expected life of 9.116 years. The change of $693,515 was recorded as loss on change in fair value of derivative liabilities for the nine months ended September 30, 2023. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the nine months ended September 30, 2023 and 2022: Balance, December 31, 2022 $ 1,648,831 Issuance of shares in exchange for convertible note payable (624,490 ) Issuance of convertible notes payable 1,265,000 Mark to market 84,463 Balance, September 30, 2023 $ 2,373,804 Loss (Gain) on change in derivative liabilities for the nine months ended September 30, 2023 $ (609,053 ) Loss on Change in Fair Value of derivative liability for the three months ended September 30, 2023 84,463 Balance, December 31, 2021 $ - Issuance of convertible notes payable 2,641,846 Derivative liabilities on settlement of note transferred to gain on settlement (227,459 ) Mark to Market during the nine months ended September 30, 2022 $ (418,769 ) Balance September 30, 2022 1,995,618 Loss on change in derivative liabilities for the nine months ended September 30, 2022 500,887 Loss (Gain) on Change in Fair Value of derivative liability for the three months ended September 30, 2022 $ (418,769 ) Derivative liability- insufficient shares Certain of the Company’s embedded conversion features on debt, convertible preferred stock and outstanding options & warrants are treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 840-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. In the case of insufficient authorized share capital available to fully settle outstanding contracts, the Company utilizes the earliest maturity date sequencing method to reclassify outstanding contracts as derivative instruments. These contracts are recognized currently in earnings until such time as the convertible notes or preferred stock or option or warrants are exercised, expire, the related rights have been waived and/or the authorized share capital has been amended to accommodate settlement of these contracts. These instruments do not trade in an active securities market. On September 19, 2023, the Company estimated the fair value of the embedded derivatives of using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 154.03%, (3) risk-free interest rate of 3.88%, and (4) expected life of 2.75-9.92 years. Because of numerous issue dates weighted average exercise price and life were used to value options. Warrants were valued at the lowest exercise price because of numerous issue dates and lack of materiality of the calculation. The liability outstanding on the date of satisfaction, September 20, 2023, was $3,238,429 which was credited to additional paid in capital. During the Quarter ended September 30, 2023, the Company increase the authorized capital from 300,000,000 shares to 1,000,000,000 shares and therefore there is sufficient authorized capital as of September 30 2023, results into no short share derivative liability accrual needed and so reclass the same to additional paid in capital as per ASC 815. The Company recorded $-0- as derivative liability – insufficient shares for the nine months of September 30, 2023 and $-0- for the nine months ended September 30, 2022. The Company recorded $-0- as derivative liability – insufficient shares for the three months of September 30, 2023 and $-0- for the three months ended September 30, 2022.

STOCK INCENTIVE PLAN

STOCK INCENTIVE PLAN	9 Months Ended
	Sep. 30, 2023
STOCK INCENTIVE PLAN
STOCK INCENTIVE PLAN	NOTE 11: STOCK INCENTIVE PLAN On May 29, 2015, the Company adopted its 2015 Stock Incentive Plan. Under the Plan the Company may issue up to 10,000,000 S-8 shares to officers, employees, directors or consultants for services rendered to the Company or its affiliates or to incentivize such parties to continue to render services. S-8 shares are registered immediately upon the filing of the Plan and are unrestricted shares that are free-trading upon issuance. On April 19, 20221 the board consent increased the issue up to 40,000,000 shares. As of September 30, 2023 and December 31, 2022 respectively, there were 15,881,671 and 9,806,000 shares available for issuance under the Plan. On August 2, 2021, Bijan Pedram the Senior Scientific of Sapphire Biotechnology was granted the options to purchase 0.1 million shares of Axim common stock under the plan at the purchase price of $0.67 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day and the balance of the option shares will be vested of thirty-six (36) successive equal monthly in the first anniversary of the vesting commencement day. On August 17, 2021, Jeff Busby the Senior Vice president of Sales of Axim Biotechnology was granted the options to purchase 1 million of shares of Axim common stock under the plan at the purchase price of $0.60 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day. On September 1, 2021, Laura M. Periman Medical advisory board member of Axim Biotechnology was granted the options to purchase 0.1 million of shares of Axim common stock under the plan at the purchase price of $0.64 per share. 50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day. On September 4, 2021, Kelly K. Nichols Medical advisory Board member of Axim Biotechnology was granted the options to purchase 0.1 million of shares of Axim common stock under the plan at the purchase price of $0.62 per share. 50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day. On September 8, 2021, Joseph Tauber the Ophthalmic Chief Medical Officer (CMO) of Axim Biotechnology was granted the options to purchase 1 million of shares of Axim common stock under the plan at the purchase price of $0.622 per share. 25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day. On August 22, 2022, 13,500,000 options were issued with a strike price of $0.052; 5,750,000 vesting immediately and the balance vesting between nine months and a year from issuance. On December 9, 2022, 900,000 options were issued with a strike price of $0.10; all of them vesting immediately. The Company estimated the fair value of the Option value of $.04 using the Black-Scholes Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 227%, (3) risk-free interest rate of 3.03%, and (4) expected life of 9.9 years. For the three and nine months ended September 30, 2023 and 2022 respectively the Company recorded compensation expense of $38,415, $163,641 and $517,180, $888,313 respectively.

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	9 Months Ended
	Sep. 30, 2023
STOCKHOLDERS DEFICIT
STOCKHOLDERS' DEFICIT	NOTE 12: STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 5,000,000 shares of preferred stock, with a par value of $0.0001 per share. Of the 5,000,000 authorized preferred shares, 4,000,000 are undesignated “blank check” preferred stock. The Company may issue such preferred shares and designate the rights, privileges and preferences of such shares at the time of designation and issuance. As of September 30, 2023, and December 31, 2022 there are -0- and -0- shares of undesignated preferred shares issued and outstanding, respectively. There are zero 0 shares issued and outstanding of Series A and Series B Preferred stock as of September 30, 2023. Series C Convertible Preferred Stock On August 17, 2016 the Company designated up to 500,000 shares of a new Series C Convertible Preferred Stock (Series C Preferred Stock). The holders of the Series C Preferred are entitled to elect four members to the Company’s board of directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. Each share of Series C Convertible Preferred is convertible into one share of the Company’s common stock. The Series C Convertible Preferred designation contains a number of protective and restrictive covenants that restrict the Company from taking a number of actions without the prior approval of the holders of the Series C Preferred or the unanimous vote of all four Series C Directors. If at any time there are four Series C Directors, one such director must be independent as that term is defined in the Series C designation. Any challenge to the independence of a Series C Director is a right conferred only upon the holders of the Series B Convertible Preferred Stock and may only be made by the holders of the Series B Convertible Preferred Stock. On August 18, 2016 the Company issued all 500,000 shares of its newly designated Series C Preferred Stock to MJNA Investment Holdings, LLC in exchange for cash of $65,000. As the holders of the Series C Preferred Stock, MJNA Investment Holdings, LLC has designated Dr. Timothy R. Scott, John W. Huemoeller II, Robert Cunningham and Blake Schroeder as their four Series C Directors. On February 20, 2019, MJNA Investment Holdings LLC (“Seller”) sold its 500,000 shares of AXIM Biotechnologies, Inc.’s, a Nevada corporation (the “Company”) Series C Preferred Stock to Juniper & Ivy Corporation, a Nevada corporation (“Purchaser”) for a purchase price of $500,000 (the “Purchase Price”) pursuant to a Preferred Stock Purchase Agreement (the “Purchase Agreement”). Payment of the Purchase Price was made as follows (i) a $65,000 payment made by check payable to Seller, which Purchaser borrowed from an unrelated third-party and which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Loan”), and (ii) the issuance by Purchaser to Seller of a promissory note, face value, $435,000, which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Note”). The Company’s Chief Executive Officer John W. Huemoeller II is the President of Purchaser. Mr. Huemoeller provided a personal guaranty for the Loan and the Note. The holders of the Series C Preferred Stock are entitled to elect four members to the Company’s Board of Directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. As a result of this transaction, a change in control has occurred. Common Stock The Company has authorized 1,000,000,000 shares of common stock, with a par value of $0.0001 per share. As of September 30, 2023 and December 31, 2022, the Company had 237,649,403 and 192,441,917 shares of common stock issued and outstanding, respectively. 2023 Transactions: One million shares were issued in satisfaction of Common stock to be issued Valued at $135,000 ($0.135 per share) closing price of the Company’s stock at May 4, 2020 of the agreement to purchase the promissory note in exchange for which the shares were issued. Twenty Two million shares were issued during the first nine months of 2023 pursuant to the Company’s S-1 in exchange for $452,775. The company has received an advance from the shareholder in the amount of $105,170; at this time there are no plans to offset this amount against S-1 proceeds. It will be repaid as cash flow allows. 22,207,486 shares were issued due to conversion of Notes Payable and accrued interest Theron valued at $688,432 closing price of company’s stock on date of issuance. 2022 Transactions: During January 2022, the Company issued 519,247 shares for cash of gross proceeds of $75,000 pursuant to various stock purchase agreements. The cash was received in the fourth quarter 2021 and first quarter 2022. The Company also issued warrants to purchase an aggregate of 519,247 shares of common stock at an average exercise price of $0.315 per share. The warrants are exercisable within a 3-year period from issuance. In January 2022, the Company issued 7,000,000 shares of its common stock pursuant to its asset acquisition of Advanced Tear Diagnostics which was under common stock to be issued. In January 2022, the Company issued 302,115 of its shares of common stock, valued at $100,000, in exchange for services which have been recorded as a prepaid expense. On January 11, 2022, the company issued 282,759 shares of common stock upon the exercise of 500,000 options at an exercise price of $0.126 a share. This exercise was performed on a cashless basis. In March 2022, the Company issued 624,290 of its shares of common stock pursuant to a stock purchase agreement for cash gross proceeds of $55,000. In March 2022, the Company issued 173,390 shares of its common stock, valued at $32,944, in settlement of interest due to prepayment of a note. In March 2022, the company issued 500,000 of its shares of common stock, valued at $79,500 in exchange for services related to the arrangement of meetings and conferences. The Company also issued 10,750,000 shares of its common stock January thru June of 2022 for cash of $973,495 pursuant to an equity purchase agreement, dated on May 14, 2021, which shares were registered pursuant to that S-1 Registration Statement filed by the Company with the SEC on May 14, 2021, and declared effective by the SEC on June 22, 2021. The Company issued 891,610 of its shares to settle the amounts owed to George Anastassov and Lekhram Changoer. The debt totaled $60,000 and the company recognized a loss on settlement of $4,196. The Company issued 3,544,247 of its shares in settlement of claims made by individuals pursuant to various stock Purchase agreements. The company recognized a current period loss of $226,171 as a result of this settlement. During the third quarter 2022 the company issued 2,227,638 shares pursuant to its S-1 for cash of $78,928. On July 14, 2022, the Company entered into the Equity Purchase Agreement with Cross & Company, pursuant to which we have the right to “put,” or sell, up to $30,000,000 worth of shares of our common stock to Cross. As provided in the Equity Purchase Agreement, we may require Cross to purchase shares of our common stock from time to time by delivering a put notice to Cross specifying the total number of shares to be purchased (such number of shares multiplied by the purchase price described below, the “Investment Amount”); provided there must be a minimum of ten trading days between delivery of each put notice. We may determine the Investment Amount, provided that such amount may not be more than 300% of the average daily trading volume in dollar amount for our common stock during the five trading days preceding the date on which we deliver the applicable put notice, unless waived by Cross in its sole discretion. Additionally, such amount may not be lower than $10,000 or higher than $250,000. Cross will have no obligation to purchase shares under the Equity Line to the extent that such purchase would cause Cross to own more than 4.99% of our issued and outstanding shares of common stock. The Company also issued 8,000,000 shares of its common stock January thru December of 2022 for cash of $234,844 and a subscription receivable of $46,000 under an equity purchase agreement, dated on July 14, 2022, which shares were registered pursuant to that S-1 Registration Statement filed by the Company with the SEC on July 25, 2022, and declared effective by the SEC on August 4, 2022. The subscription amount of $46,000 was received subsequent to December 31 2022. This was shown as subscription receivable on the equity statement. The company received advance of $47,720 that will be offset against future puts. Also during the third quarter of 2022 the company issued 13,861,004 shares pursuant to various stock purchase agreements for cash of $350,000. The Company converted debt of $177,840 during 2022 including accrued interest of $2,840 in exchange for 5,665,636 shares of its stock valued at $349,535 and as a result recognized a loss on extinguishment of $111,807, including cancellation of balance debt discount of $167,571 and a gain due to cancellation of derivative liabilities as of date of settlement of $227,459.

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended
	Sep. 30, 2023
STOCK OPTIONS AND WARRANTS
STOCK OPTIONS AND WARRANTS	NOTE 13: STOCK OPTIONS AND WARRANTS Options to purchase common stock are granted at the discretion of the Board of Directors, a committee thereof or, subject to defined limitations, an executive officer of the Company to whom such authority has been delegated. Options granted to date generally have a contractual life of ten years. The stock option activity for nine months ended September 30, 2023 and year ended December 31, 2022 respectively is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2021 10,960,715 $ 0.37 Granted 14,400,000 0.0405 Exercised (500,000 ) 0.002 Expired or cancelled (3,000,000 ) 0.057 Outstanding at December 31, 2022 21,860,715 $ 0.049 Granted 3,000,000 0.02 Expired (742,386 ) - Balance September 30, 2023 24,118,329 $ 0.13 The following table summarizes the changes in options outstanding, option exercisability and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at September 30, 2023: As of September 30, 2023 Schedule of option outstanding under stock option plan Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.15 24,118,329 8.25 $ 0.13 22,535,024 $ 0.14 As of December 31, 2022 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.15 19,860,715 9.0 $ 0.049 18,341,741 $ 0.049 The Company determined the value of share-based compensation for options vested using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: September 30, December 31, 2023 2022 Expected life (years) 10 10 Risk-free interest rate (%) 3.53 3.96 Expected volatility (%) 2.24 2.29 Dividend yield (%) - - Weighted average fair value of shares at grant date $ - $ 1.74 For the three and nine months ended September 30, 2023 and 2022 stock-based compensation expense related to vested options was $38,415, $182,215 and $517,180, $888,313 respectively. Warrants The following table summarizes warrant activity during the year ended December 31, 2022 and the nine months ended September 30, 2023: Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2021 3,025,000 $ 0.71 Granted 519,247 0.31 Forfeited/Cancelled - - Exercised - - Outstanding at December 31, 2022 3,544,247 $ 0.65 Granted - - Exercised - - Expired - - Outstanding at September 30, 2023 3,544,247 0.65 All outstanding warrants are exercisable at September 30, 2023 and there was no unrecognized stock-based compensation expense related to warrants.

COMMITMENT AND CONTINGENCIES

COMMITMENT AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
COMMITMENT AND CONTINGENCIES
COMMITMENT AND CONTINGENCIES	NOTE 14: COMMITMENT AND CONTINGENCIES On January 2, 2019 the Company entered into the term of Executive’s employment agreement, at a base salary of $10,000 per month with John W. Huemoeller II to serve as its Chief Executive Officer. The Company and Executive acknowledge and agree that Executive’s employment hereunder shall at all times be “at will,” which means that either Executive may resign at any time for any reason or for no reason, and that the Company may terminate Executive’s employment at any time for any reason or for no reason, in either case, subject to the applicable provisions of this Agreement. In further consideration for Executive’s services and subject to the approval of the Board, Executive will be granted an option to purchase 2,000,000 shares of the Company’s common stock (the “Option Shares”). The option will be subject to the terms and conditions applicable to stock options granted under the Company’s 2015 Stock Incentive Plan, as amended from time to time (the “Plan”), and as described in the Plan and the stock option agreement, which Executive will be required to sign. 50% of the Option Shares shall vest on the date of grant and the remaining 50% of the Option Shares shall vest on the 12- month anniversary of the grant date, subject to Executive’s continued employment by the Company. The exercise price per share will be equal to the fair market value per share on the date of grant, as determined by the last closing price of the Company’s common stock the day prior to grant. Beginning in October 2019, the board decided to increase CEO base salary to $35,000 per month. During the three and nine months expenses September 30 2023 and 2022, the Company incurred $30,765, $105,000 and $153,102, $275,000, respectively. On April 24, 2017 the company entered into an employment agreement with Robert Malasek, its Chief Financial Officer and Secretary. The agreement does not have a set term and may be terminated at any time by the Company or Mr. Malasek with proper notice. The shares were issued in the 1 st Industry Sponsored Research Agreement— Sapphire entered into the Industry Sponsored Research Agreement (“SRA”) effective February 7, 2020 to test and confirm the inhibitory activity of SBI-183 (exclusively licensed on January 13, 2020) and SBI-183 analogs, including those synthesized by the Company. The testing will include cell-based in vitro assays, NMR binding studies and testing to determine if SBI-183 enhances the activity of cytotoxic drugs in vitro. Animal studies will also be conducted under the SRA. Specifically, SBI-183 analogs will be evaluated in a mouse model of triple negative breast cancer using human tumor xenografts. The work will be performed over a period of one year with the total cost of the SRA totalling $150,468 paid prior to acquisition. For the year December 31, 2021, the Company recorded research and development expenses of $284,869. The agreement is now being renegotiated. On August 5, 2020 Sapphire was awarded a $395,880 phase I Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The grant will support continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (QSOX1) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, invasion and metastasis. Sapphire is conducting this research with technology it has exclusively licensed from Skysong Innovations, LLC, the intellectual property management company for Arizona State University. Sapphire will subcontract tumor biology work for evaluating analog inhibitors for QSOX1 to Dr. Doug Lake’s laboratory at Arizona State University and Mayo Clinic Arizona. Grant income received for the years ended 2021 was $279,981. There was nil in 2022. On August 25, 2020 we signed an exclusive licensing, manufacturing and distribution agreement with Empowered Diagnostics LLC to execute the high-volume production of our rapid point-of-care diagnostic test. AXIM and Empowered have completed the technology transfer and Empowered Diagnostics has built out their production facility to be able to manufacture millions of our neutralizing antibody tests for COVID-19 per month. In exchange for this license Empowered will pay Axim a royalty on net sales on all licensed products sold by Empowered covered by this license which global with the exception of Mexico. This agreement was cancelled in February, 2022. On September 15, 2022, the company entered into a license and distribution agreement for its Lactoferrin dry eye test, Ige allergy test for allergic conjunctivitis and quantitative MMp-9 test to identify ocular surface inflammation. The licensee is Versea Ophthalmics, LLC, A Delaware Limited Liability Company. The agreement will provide Verséa with the exclusive commercial right to AXIM’s proprietary portfolio of point-of-care (POC) lab testing readers and three key biomarker diagnostic tests designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient Dry Eye Disease and non-specific allergic conjunctivitis. The three AXIM’s key biomarker tests – the Ocular Immunoglobulin E (IgE) test, the Lactoferrin test, and the future MMP-9 test – require the collection of 0.5 microliters in tears and provide quantitative results in under 10 minutes, an industry-leading return time. Verséa plans to launch IgE and Lactoferrin tests at the upcoming 2022 American Academy of Ophthalmology (AAO) and American Academy of Optometry (AAOPT) conferences. The MMP-9 test is anticipated to follow in the next 18-24 months. Versea plans to launch sales sometime in fourth quarter 2023. During first quarter 2023 further modification of the tests and packaging took place. Operating Lease Lease Agreement—On March 3, 2020, Sapphire entered into a 3-year lease agreement (“Lease”) to relocate to a larger space within the same business park. The new space totals 1,908 square feet with monthly base rent in the 1st year $4,713, 2nd year $4,854 and 3rd year $5,000 at implicit interest rate of 6%. A new lease is effective April 25, 2023. Upon commencement of the Lease on April 25, 2023, the previous lease will expire. The company has renewed the lease effective May 1, 2023. The following table sets forth the revised schedule of the monthly Base Rent payable for the Premises during the Extended Term: Month(s) of Term No. of Months Monthly Base Rent Conditionally Abated Monthly Base Rent Total Monthly Base Rent May 1, 2023 – May 31, 2023 1 $ 8,014.00 $ 8,014.00 June 1, 2023 – September 30, 2023 1 $ 8,014.00 $ 8,014.00 $ 8,014.00 July 1, 2023 – April 30, 2024 10 $ 8,014.00 $ 8,014.00 May 1, 2024 – April 30, 2025 12 $ 8,335.00 $ 8,334.00 May 1, 2025 – April 30, 2026 12 $ 8,668.00 $ 8,668.00 May 1, 2026 – May 31, 2026 1 $ 9,014.00 $ 9,014.00 Operating Leases - Right of Use Assets and Purchase Commitments Right of Use Assets We have operating leases for office space that expire through 2023. Below is a summary of our right of use assets and liabilities as of September 30,2023. Right-of-use assets $ 248,719 Lease liability obligations, current $ 91,672 Lease liability obligations, noncurrent 162,410 Total lease liability obligations $ 254,082 Weighted-average remaining lease term 2.50 years Weighted-average discount rate 6 % The following table summarizes the lease expense for the three and nine months ended September 30, 2023 and 2022 respectively: Three months ended September 30, September 30, 2023 2022 Operating lease expense $ 26,401 * $ 14,854 Short-term lease expense 11,637 24,700 Total lease expense $ 38,038 $ 39,554 Nine months ended September 30, September 30, 2023 2022 Operating lease expense $ 70,633 * $ 37,203 Short-term lease expense 34,911 15,516 Total lease expense $ 105,544 $ 52,719 *We recorded $36,765 of operating lease expense this includes $11,637 of maintenance charges and month to month lease for the three months ended September 30, 2023 and $39,554 with $24,700 of maintenance and month to month charges for the three months ended September 30, 2022. *We recorded $70,633 of operating lease expense this includes $34,911 of maintenance charges and month to month lease for the nine months ended September 30, 2023 and $52,719 with $15,516 of maintenance and month to month charges for the nine months ended September 30, 2022. Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of September 30, 2023, are as follows: 2023 $ 24,042 2024 106,750 2025 102,684 2026 43,686 Total minimum payments 277,162 Less: amount representing interest (23,080 ) Total $ 254,082 Litigation Litigation: The company has been named as a defendant in the following legal action: Innovative Medical Supplies, LLC v. Advanced Tear Diagnostics, LLC, Case No. 37-2021-00032000-CU-FR-CTL filed in the Superior Court of the State of California, County of San Diego. Allegations: The Company has been named as a defendant in this litigation. The Second Amended Complaint (“SAC”) alleges causes of action of Fraud; Conspiracy to Defraud; Unjust Enrichment/Constructive Trust, Intentional Interference with Contract; and Interference with Economic Relations against the Company. The SAC prays for relief of Compensatory damages and other Special, general and consequential damages of not less than $280,586 as well as Punitive and exemplary damages and attorney fees and cost of suit. AXIM Demurred and brought a Motion to Strick as to the SAC. That motion is pending before the Court. Status: The litigation is in the pleading stage as against the Company and the Company has responded to the SAC but has not answered the SAC pending the outcome of its Demurrer and Motion to Strike. Settlement: The Company has entered into a Settlement Agreement with the Plaintiff’s manager to fully resolve the matter in its entirety. However, there is a dispute as to who has control over the Plaintiff limited liability company. The Court has scheduled an Evidentiary hearing with the intent to resolve the control issue and the enforceability of the Settlement Agreement. At this time the company believes it is more likely than not that it will prevail in the lawsuit. Therefore, no loss provision has been accrued in these financial statements.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 15: SUBSEQUENT EVENTS Common Stock Issuances During October and November 2023, the Company did not issue any additional shares on their S-1. The company has received $80,170 in advances from the shareholder as of September 30; on During October 2023 an additional $75,000 was received in the account towards the advance. At this time there are no plans to offset this amount against S-1 proceeds. It will be repaid as cash flow allows.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2023
BASIS OF PRESENTATION
Use of estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Significant estimates are estimates of discount rates in lease, assumptions about collection of useful life of intangible assets and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate.
Operating lease	We lease property under various operating leases which are disclosed on our consolidated Balance sheet in accordance with ASC 842.
Risks and uncertainties	The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Form 10-K.
Cash equivalents	The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of September 30, 2023, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at September 30, 2023 and December 31, 2022. The Company has never experienced any losses related to these balances.
Accounts Receivable	It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers.
Concentrations	At September 30, 2023 and December 31, 2022, there were no accounts receivable. For the three and nine months ended September 30, 2023 one customer accounted for 100% of total revenue. For the three and nine months ending September 30, 2022 one customer accounted for 100% of total revenue.
Property and equipment	Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. The Company’s property and equipment consisted of the following at September 30, 2023 and December 31, 2022, respectively. September 30, 2023 December 31, 2022 Equipment $ 183,992 $ 183,992 Less: accumulated depreciation $ 114,582 $ 90,152 $ 69,410 $ 93,840 Depreciation expense was $8,143, $24,429 and $8,143, $23,451 for the three and nine months ended September 30, 2023 and 2022, respectively.
Intangible Assets	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. We conduct an impairment analysis for goodwill annually in the fourth quarter or more frequently if indicators of impairment exist or if a decision is made to sell or exit a business. Significant judgments are involved in determining if an indicator of impairment has occurred. Such indicators may include deterioration in general economic conditions, negative developments in equity and credit markets, adverse changes in the markets in which an entity operates, increases in input costs that have a negative effect on earnings and cash flows, or a trend of negative or declining cash flows over multiple periods, among others. The fair value that could be realized in an actual transaction may differ from that used to evaluate the impairment of goodwill. We first may assess qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the quantitative goodwill impairment test included in U.S. GAAP. To the extent our assessment identifies adverse conditions, or if we elect to bypass the qualitative assessment, goodwill is tested using a quantitative impairment test. Impairment of Indefinite-Lived Intangible Assets For indefinite-lived intangible assets such as in-process research and development (IPRD), we conduct an impairment analysis annually in the fourth quarter or more frequently if indicators of impairment exist. We first perform a qualitative assessment to determine if it is more likely than not that the carrying amount of each of the in-process research and development assets exceeds its fair value. The qualitative assessment requires the consideration of factors such as recent market transactions, macroeconomic conditions, and changes in projected future cash flows. If we determine it is more likely than not that the fair value is less than its carrying amount of the in-process research and development assets, a quantitative assessment is performed. The quantitative assessment compares the fair value of the in-process research and development assets to its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized for the excess. We elected to perform a quantitative assessment of indefinite-lived intangible assets and determined that the fair value of the goodwill and IPRD related to the Sapphire acquisition was less than its carrying amount and that in-process research and development were fully impaired. The Company’s intangible assets consisted of the following at September 30, 2023 and December 31, 2022, respectively. September 30, December 31, 2023 2022 Patents $ 250,000 $ 250,000 Licenses 4,270,000 4,270,000 4,520,000 4,520,000 Less: accumulated amortization 826,407 530,573 $ 3,693,593 $ 3,989,427 Estimated aggregate amortization expense for each of the five succeeding years ending December 31 is as follows: 2023 2024 2025 2026 2027 2028 and thereafter Amortization expense $ 97,405 $ 389,123 $ 389,123 $ 389,123 $ 389,123 $ 2,039,696 Amortization expense recorded for the three and nine months ended September 30, 2023 and 2022 was $98,612, $98,612 and $295,836, $295,836 respectively.
Revenue Recognition	The Company follows the guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. All revenue was from operations that were divested. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from operations recognized for three and nine months ended September 30, 2023 and 2022 amounted to $9,581, $1,314 and $26,659, $1,314 respectively.
Fair Value Measurements	The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The Company’s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, notes payable, and long-term debt. The recorded values of cash and cash equivalents and accounts payable approximate their fair values based on their short-term nature. The recorded values of notes payable and long-term debt approximate their fair values, as interest approximates market rates. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The Company recognizes its derivative liabilities as Level 3 and values its derivatives using the methods discussed below. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed are that of volatility and market price of the underlying common stock of the Company. Items recorded or measured at fair value on a recurring basis in the accompanying condensed consolidated financial statements consisted of the following items as of September 30, 2023. Total Level 1 Level 2 Level 3 Derivative liabilities $ 2,373,804 $ - $ - $ 2,373,804 December 31, 2022 Total Level 1 Level 2 Level 3 Derivative liabilities $ 1,648,831 $ - $ - $ 1,648,831
Convertible Instruments	The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities.” Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.
Income Taxes	The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. No amounts were accrued for the payment of interest and penalties as of September 30, 2023 and December 31, 2022 respectively. The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the Nine months ended September 30, 2023 and 2022 respectively. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “Cares Act”) was enacted. The CARES Act included loans and grants to certain businesses, and temporary amendments to the Internal Revenue Code which changed net loss carryforward and back provisions and the business interest expenses limitation. Under the CARES Act provisions, the most relevant income tax considerations to Oncocyte relate to the amounts received under the Paycheck Protection Program loan program and the possible forgiveness of those loans by the SBA. On December 21, 2020, the U.S. president has signed into law the “Consolidated Appropriations Act, 2021” which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven PPP loans can deduct regular business expenses that are paid for with the loan proceeds for federal tax purposes. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant.
Concentrations of Credit Risk	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company had $0 and $0 allowance for doubtful accounts at September 30, 2023 and 2022, respectively and had $0 accounts receivable at September 30, 2023 and $0 at December 31, 2022.
Net Loss per Common Share	Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were common share equivalents 254,739,838 at September 30, 2023 and 47,298,693 at December 31, 2022. For the Period ended September 30, 2023 these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. If necessary, the company would increase authorized shares to honour conversion agreements. The company recognized a derivative short share expense for the three and nine months ending September 30, 2023 in the amounts of $(432,350) and $3238,429 respectively as a result of authorized shares being insufficient to redeem convertible securities and notes. This was resolved in Quarter ending September 30, 2023. During the Quarter ended September 30, 2023, the Company increased the authorized capital from 300,000,000 to 1,000,000,000 shares and therefore there is sufficient authorized capital as of September 30, 2023, results into no short share derivative liability accrual needed and so reclass the same to additional paid in capital as per ASC 815.
Stock Based Compensation	All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. The Company accounts for stock options issued to non-employees based on the estimated fair value of the awards using the Black-Scholes option pricing model in accordance with ASC 505-50, Equity-Based Payment to Non-employees
Research and Development	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. For the three and nine months ended September 30, 2023 and 2022 the Company incurred research and development expenses of $34,713, $29,722 and $89,123, $109,086, respectively. The Company has entered into various agreements with CROs. The Company’s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. Material Equity Instruments The Company evaluates stock options, stock warrants and other contracts (convertible promissory note payable) to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for under the relevant sections of ASC 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity (“ASC 815”). Certain of the Company’s embedded conversion features on debt and outstanding warrants are treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 840-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1)earliest issuance date or (2) latest maturity date. In the case of insufficient authorized share capital available to fully settle outstanding contracts, the Company utilizes the earliest maturity date sequencing method to reclassify outstanding contracts as derivative instruments. These contracts are recognized currently in earnings until such time as the convertible notes or warrants are exercised, expire, the related rights have been waived and/or the authorized share capital has been amended to accommodate settlement of these contracts. These instruments do not trade in an active securities market.
Recently Issued Accounting Standards	Accounting Standards Implemented Since December 31, 2022 ASC Update 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this Update do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic. That is, accounting for those instruments continues to be subject to the requirements in other Topics. The amendments in this Update do not affect a holder’s accounting for freestanding call options. ASC Update No. 2020-10 In October 2020, the FASB issued ASC Update No. 2020-10, Codification Improvements. Update No. 2020-10 amends a wide variety of Topics in the Codification in order to improve the consistency of the Codification and the application thereof, while leaving Generally Accepted Accounting Principles unchanged. ASC Update No. 2020-06 In August 2020, the FASB issued ASC Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in Update No. 2020-06 simplify the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity’s own equity. Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2023
BASIS OF PRESENTATION
Schedule of property and equipment relating to continuing operations	September 30, 2023 December 31, 2022 Equipment $ 183,992 $ 183,992 Less: accumulated depreciation $ 114,582 $ 90,152 $ 69,410 $ 93,840
Schedule of intangible assets relating to continuing operation	September 30, December 31, 2023 2022 Patents $ 250,000 $ 250,000 Licenses 4,270,000 4,270,000 4,520,000 4,520,000 Less: accumulated amortization 826,407 530,573 $ 3,693,593 $ 3,989,427
Estimated aggregate amortization expense	2023 2024 2025 2026 2027 2028 and thereafter Amortization expense $ 97,405 $ 389,123 $ 389,123 $ 389,123 $ 389,123 $ 2,039,696
Derivative liabilities measured at fair value on recurring basis	Total Level 1 Level 2 Level 3 Derivative liabilities $ 2,373,804 $ - $ - $ 2,373,804 Total Level 1 Level 2 Level 3 Derivative liabilities $ 1,648,831 $ - $ - $ 1,648,831

PREPAID EXPENSES (Tables)

PREPAID EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2023
PREPAID EXPENSES
Schedule of prepaid expenses	September 30, December 31, 2023 2022 Prepaid insurance $ - $ 42,078 Prepaid interest - 780 $ - $ 42,858

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2023
CONVERTIBLE NOTES PAYABLE
Schedule of convertible note payable,related party	September 30, December 31, 2023 2022 Convertible note payable, due on November 1, 2026, interest at 3.5% p.a. $ 4,000,000 $ 4,000,000 Accrued interest 105,000 261,537 Convertible note payable, net $ 4,105,000 $ 4,261,537
Schedule of convertible notes payable	September 30, December 31, 2023 2022 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. (1) $ 484,478 $ 484,478 Convertible Note Payable, due on January 27,2032 interest at 3% p.a. (4) 367,931 367,931 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. (2) 500,000 500,000 Convertible note payable, due on February 10, 2032, interest at 3.0% p. a. (5) 800,000 1,150,000 Convertible note payable, due on December 31, 2034, interest at 3% p.a. (3) 190,000 190,000 Convertible note payable, due on May 23, 2033, interest at 3.75% p.a. 250,000 - Convertible note payable, due on May 23, 2033, interest at 3.75% p.a. 325,000 - Accrued interest (The accrued interest and principal are both included in the captions titled “convertible note payable” in the balance sheet) 70,061 274,442 Total 2,987,470 2,966,851 Less: unamortized debt discount/finance premium costs (1,557,786 ) (1,583,435 ) Convertible note payable, net $ 1,429,684 $ 1,383,416

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
BASIS OF PRESENTATION
Summary of changes in fair value of financial liabilities	Balance, December 31, 2022 $ 1,648,831 Issuance of shares in exchange for convertible note payable (624,490 ) Issuance of convertible notes payable 1,265,000 Mark to market 84,463 Balance, September 30, 2023 $ 2,373,804 Loss (Gain) on change in derivative liabilities for the nine months ended September 30, 2023 $ (609,053 ) Loss on Change in Fair Value of derivative liability for the three months ended September 30, 2023 84,463 Balance, December 31, 2021 $ - Issuance of convertible notes payable 2,641,846 Derivative liabilities on settlement of note transferred to gain on settlement (227,459 ) Mark to Market during the nine months ended September 30, 2022 $ (418,769 ) Balance September 30, 2022 1,995,618 Loss on change in derivative liabilities for the nine months ended September 30, 2022 500,887 Loss (Gain) on Change in Fair Value of derivative liability for the three months ended September 30, 2022 $ (418,769 )

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2023
STOCK OPTIONS AND WARRANTS
Schedule of stock option activity	Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2021 10,960,715 $ 0.37 Granted 14,400,000 0.0405 Exercised (500,000 ) 0.002 Expired or cancelled (3,000,000 ) 0.057 Outstanding at December 31, 2022 21,860,715 $ 0.049 Granted 3,000,000 0.02 Expired (742,386 ) - Balance September 30, 2023 24,118,329 $ 0.13
Schedule of option outstanding under stock option plan	Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.15 24,118,329 8.25 $ 0.13 22,535,024 $ 0.14 Options Outstanding Options Exercisable Weighted Average Exercise Price ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.15 19,860,715 9.0 $ 0.049 18,341,741 $ 0.049
Schedule of weigted average assumptions using black holes option pricing model	September 30, December 31, 2023 2022 Expected life (years) 10 10 Risk-free interest rate (%) 3.53 3.96 Expected volatility (%) 2.24 2.29 Dividend yield (%) - - Weighted average fair value of shares at grant date $ - $ 1.74
Schedule of warrants activity	Number of Warrants Weighted Average Exercise Price Outstanding at December 31, 2021 3,025,000 $ 0.71 Granted 519,247 0.31 Forfeited/Cancelled - - Exercised - - Outstanding at December 31, 2022 3,544,247 $ 0.65 Granted - - Exercised - - Expired - - Outstanding at September 30, 2023 3,544,247 0.65

COMMITMENT AND CONTINGENCIES (T

COMMITMENT AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2023
COMMITMENT AND CONTINGENCIES
Summary of monthly base rent payable for the premises during extended term	Month(s) of Term No. of Months Monthly Base Rent Conditionally Abated Monthly Base Rent Total Monthly Base Rent May 1, 2023 – May 31, 2023 1 $ 8,014.00 $ 8,014.00 June 1, 2023 – September 30, 2023 1 $ 8,014.00 $ 8,014.00 $ 8,014.00 July 1, 2023 – April 30, 2024 10 $ 8,014.00 $ 8,014.00 May 1, 2024 – April 30, 2025 12 $ 8,335.00 $ 8,334.00 May 1, 2025 – April 30, 2026 12 $ 8,668.00 $ 8,668.00 May 1, 2026 – May 31, 2026 1 $ 9,014.00 $ 9,014.00
Summary of right of use asset and liabilities	Right-of-use assets $ 248,719 Lease liability obligations, current $ 91,672 Lease liability obligations, noncurrent 162,410 Total lease liability obligations $ 254,082 Weighted-average remaining lease term 2.50 years Weighted-average discount rate 6 %
Summary of lease expenses	Three months ended September 30, September 30, 2023 2022 Operating lease expense $ 26,401 * $ 14,854 Short-term lease expense 11,637 24,700 Total lease expense $ 38,038 $ 39,554 Nine months ended September 30, September 30, 2023 2022 Operating lease expense $ 70,633 * $ 37,203 Short-term lease expense 34,911 15,516 Total lease expense $ 105,544 $ 52,719
Schedule of future minimum rental payments for operating leases	2023 $ 24,042 2024 106,750 2025 102,684 2026 43,686 Total minimum payments 277,162 Less: amount representing interest (23,080 ) Total $ 254,082

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - shares	Jan. 06, 2022	May 11, 2015	Jan. 10, 2022
Exchange of common stock		5,826,706
Organization description	the record holder of 500,000 shares of the Company’s Series C Preferred Stock, representing 100% of the 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are entitled to cast a vote for election of up to four Series C Directors, whether by shareholder meeting
Schroeder [Member]
Acquisition ownership percentage			16.40%

ACQUISITION OF INTELLECTUAL P_2

ACQUISITION OF INTELLECTUAL PROPERTY OF ADVANCED TEAR DIAGNOSTIC LLC (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended
	Aug. 26, 2021	Jul. 29, 2021	Sep. 30, 2023	Dec. 31, 2022
Patents			$ 250,000	$ 250,000
TOTAL LIABILITIES			9,999,022	$ 9,037,447
Tear Diagnostics LLC [Member]
Purchase Price acquisition			$ 4,520,000
Patents		$ 250,000
TOTAL LIABILITIES		30,000
Purchase price		210,000
Monthly payments		$ 30,000
Licenses fee	$ 4,270,000
Patents average ife			11 years 6 months 14 days

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended
	Mar. 11, 2019	Apr. 16, 2018	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Working capital deficit			$ (4,254,946)
Accumulated deficit			70,282,629		$ 64,125,176
Net cash provided by (used in) operating activities			(1,050,056)	$ (1,728,821)
Additional capital raised			64,304,748		$ 59,191,469
Stock Purchase Agreement [Member]
Share sold during period		1,945,000
Share issued amount reduced	$ 400,000
Additional capital raised			$ 477,775

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
BASIS OF PRESENTATION
Equipment	$ 183,992	$ 183,992
Less: accumulated depreciation	114,582	90,152
Property, plant and equipment, net	$ 69,410	$ 93,840

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
BASIS OF PRESENTATION
Patents	$ 250,000	$ 250,000
Licenses	4,270,000	4,270,000
Finite-lived intangible assets, gross	4,520,000	4,520,000
Less: accumulated amortization	826,407	530,573
Intangible assets, net	$ 3,693,593	$ 3,989,427

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2)	Dec. 31, 2022 USD ($)
BASIS OF PRESENTATION
2023	$ 97,405
2024	389,123
2025	389,123
2026	389,123
2027	389,123
2028 and thereafter	$ 2,039,696

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Derivative liabilities	$ 2,373,804	$ 1,648,831
Fair Value, Inputs, Level 1 [Member]
Derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative liabilities	$ 2,373,804	$ 1,648,831

SIGNIFICANT ACCOUNTING POLICI_8

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Depreciation expense	$ 8,143	$ 8,143	$ 24,429	$ 23,451
Amortization expense	98,612	295,836	98,612	295,836
Revenues from continuing operations	9,581	26,659	1,314	1,314
Accrued for payment of interest and penalties	0		0		$ 0
Uncertain tax positions	0		0		0
Allowance for doubtful accounts	0		0		0
Accounts receivable	0		$ 0		$ 0
Antidilutive securities excluded from computation of earnings per share, amount			254,739,838		47,298,693
Derivative short share expense	432,350		$ 3,238,429
Research and development expense from continuing operation	$ 34,713	$ 89,123	$ 29,722	$ 109,086
One Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentrations percentage	100%	100%	100%	100%

PREPAID EXPENSES (Details)

PREPAID EXPENSES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
PREPAID EXPENSES
Prepaid insurance	$ 0	$ 42,078
Prepaid interest	0	780
Prepaid expenses	$ 0	$ 42,858

PREPAID EXPENSES (Details Narra

PREPAID EXPENSES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
PREPAID EXPENSES
Amortization of prepaid insurance	$ 0	$ 22,121	$ 42,858	$ 187,562

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	May 04, 2020	Sep. 30, 2023	Dec. 31, 2022	Mar. 17, 2020
Note receivable		$ 0	$ 0
Accrued liabilities, current		$ 0	$ 0
Dr. Sergei A. Svarovsky [Member]
Accounts payable, related parties				$ 15,000
Dr Anastassov [Member] | Purchase Promissory Note [Member] | Forbearance Agreement [Member]
Debt instrument, face amount	$ 350,000
Due to related parties, current	100,000
Note payable	100,000
Note receivable	102,567
Common stock to be issued	135,000
Loss (Gain) on extinguishment of debt	$ 32,433
Can Chew [Member]
Accounts payable, related parties				$ 15,000

DUE TO FIRST INSURANCE FUNDING

DUE TO FIRST INSURANCE FUNDING (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Jun. 25, 2022
DUE TO FIRST INSURANCE FUNDING
Insaurance renewal fee			$ 87,762
Cash down payment			8,776
Insurance financing, payments			$ 8,957
Interest rate			4.92%
Total Outstanding amount	$ 0	$ 26,781

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details) - Convertible notes payable due to shareholder - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Debt instrument, face amount	$ 4,000,000	$ 4,000,000
Accrued interest	105,000	261,537
Convertible note payable, net	$ 4,105,000	$ 4,261,537

CONVERTIBLE NOTES PAYABLE (De_2

CONVERTIBLE NOTES PAYABLE (Details 1) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Total	$ 4,105,000	$ 4,261,537
Less: unamortized debt discount/finance premium costs	(1,557,786)	(1,583,435)
Convertible Note Payable Net	1,429,684	1,383,416
Convertible note payable
Total	2,987,470	2,966,851
Accrued interest	70,061	274,442
Convertible Note Payable 1 [Member]
Total	484,478	484,478
Convertible Note Payable 2 [Member]
Total	367,931	367,931
Convertible Note Payable 3 [Member]
Total	500,000	500,000
Convertible Note Payable 4 [Member]
Total	800,000	1,150,000
Convertible Note Payable 5 [Member]
Total	190,000	190,000
Convertible Note Payable 6 [Member]
Total	250,000	0
Convertible Note Payable 7 [Member]
Total	$ 325,000	$ 0

CONVERTIBLE NOTES PAYABLE (De_3

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)			1 Months Ended					3 Months Ended				9 Months Ended		12 Months Ended
	Feb. 10, 2022	Jun. 07, 2021	May 23, 2023	Jan. 27, 2023	Jan. 23, 2023	Jan. 27, 2022	Sep. 16, 2016	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jul. 01, 2023	Mar. 17, 2020	Dec. 31, 2019	Oct. 20, 2016
Aggregate amount					$ 261,537
Accrued interest rate					3.50%	3%
Extinguishment of debt amount					$ 261,537
Interest expenses								$ 35,000		$ 105,000		$ 35,000	$ 105,000
Convertible note, principal balance					209,522			4,105,000				4,105,000		$ 4,261,537
Original maturity date						Jan. 27, 2032
Convertible note								4,105,000				4,105,000		$ 4,261,537
Convertible note beneficial conversion feature	$ 1,325,000								$ 575,000		$ 154,292
Amortization of debt discount (premium)					381,760			$ 49,820		$ 126,472		$ 46,441	132,521
Common stock price per share								$ 0.0001				$ 0.0001		$ 0.0001
Shares of convertible note						367,931
Proceeds from convertible notes												$ 575,000	$ 1,325,000
Note retired												350,000		$ 175,000
Accrued interest retired												$ 30,858		$ 2,840
Number of notes in common share												22,207,486		5,665,636
Number of notes in common share value												$ 688,432		$ 349,535
Recognized a loss on extinguishment												626,414		111,807
Cancellation of balance debt discount												318,840		167,571
Cancellation of derivative liabilities												624,490		227,459
Loss on issuance of the shares value												307,574
Debt instrument, unamortized discount								$ 1,790,886				1,790,886		1,583,435
Convertible Notes Payable [Member]
Seven convertible notes aggregate face value	1,325,000
Seven convertible notes aggregate face value convert for cash	$ 1,325,000
Convertible Debt [Member]
Original maturity date	May 23, 2033
Accrued interest rate	3.75%
Short-Term Debt [Member]
Original maturity date	Mar. 10, 2022
Short term notes face value	$ 250,000		$ 575,000
Accrued interest rate	1.50%
Short term promissory notes	$ 500,000
Secured Convertible Debt [Member]
Accrued interest								105,000				105,000		261,537
Aggregate amount					216,572
Secured Convertible Debt 1 [Member]
Accrued interest								13,000				13,000		106,467
Convertible debt								497,748				497,748		590,945
Secured Convertible Debt 3 [Member]
Accrued interest								13,497				13,497		110,104
Convertible debt								513,497				513,497		610,104
Secured Convertible Debt 4 [Member]
Accrued interest								4,276				4,276		17,116
Convertible debt								194,276				194,276		207,116
Secured Convertible Debt 2 [Member]
Accrued interest								7,369				7,369		10,262
Convertible debt								375,300				375,300		378,193
Secured Convertible Debt 7 [Member]
Accrued interest								6,861				6,861		0
Convertible debt								256,861				256,861		0
Secured Convertible Debt 8 [Member]
Accrued interest								24,361				24,361		30,492
Convertible note								$ 824,361				$ 824,361		1,180,492
CEO [Member]
Conversion price per share								$ 0.01				$ 0.01
Original maturity date												Jan. 23, 2033
Interest rate per annum								4%				4%
Amortization of debt discount (premium)					$ 250,000
Salary payable														512,500
Amount due to related party														250,000
Convertible note face value														250,000
Forfeit amount														50,000
Amount due leaving remaining balance														$ 212,500
Director [Member] | Convertible Notes Payable [Member]
Proceeds from convertible notes	$ 25,000
Convertible Note Purchase Agreement
Conversion price per share		$ 0.2201					$ 0.2201											$ 0.2201
Acquisition of common stock shares							5,000,000
Secured convertible note							$ 850,000											$ 1,000,000
Original maturity date							Oct. 01, 2029
Convertible note interest rate							3.50%											3.50%
Promissory notes																		$ 500,000
Secured promissory notes																		250,000
Convertible note		$ 500,000															$ 190,000	$ 250,000
Interest rate per annum																	3%
Additionally secured number of shares																		10,486,303
Additionally secured number of shares, value																		$ 858,828
Accrued interest		$ 82,707
Common stock conversion		2,647,464
Recognized a loss on extinguishment		$ 1,535,264
Common stock price per share																	$ 1.90
Share Exchange Agreement
Convertible note																$ 190,000
Common stock conversion																6,000,000
Minimum [Member]
Conversion price per share					$ 0.25
Maximum [Member]
Conversion price per share					$ 0.075
January 27, 2023
Aggregate amount				$ 17,115
July 1 2023 [Member] | CEO [Member]
Amount due to related party															$ 212,500

DERIVATIVE LIABILITIES (Details

DERIVATIVE LIABILITIES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
BASIS OF PRESENTATION
Balance at beginning			$ 1,648,831	$ 0
Issuance of shares in exchange for convertible note payable			(624,490)	2,641,846
Issuance of convertible notes payable			1,265,000
Derivative liabilities on settlement of note transferred to gain on settlement				(227,459)
Mark to market			84,463	(418,769)
Balance at ending	$ 2,373,804	$ 1,995,618	2,373,804	1,995,618
Loss (Gain) on change in derivative liabilities	$ 84,463	$ (418,769)	$ (609,053)	$ 500,887

DERIVATIVE LIABILITIES (Detai_2

DERIVATIVE LIABILITIES (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended				9 Months Ended
	Feb. 10, 2022	Sep. 19, 2023	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Fair value of embedded derivatives	$ 2,641,846		$ 2,982,856				$ 2,982,856
Beneficial conversion feature	1,325,000			$ 575,000		$ 154,292
Non-cash interest expenses	$ 1,316,846
Loss on change in derivative liabilities							693,515
Derivative liability			0		$ 0		0	$ 0
Liability outstanding			$ 3,238,429				$ 3,238,429
Measurement Input, Expected Dividend Rate [Member]
Derivative liability measurment input assumption	0%	0%	0%				0%
Measurement Input, Price Volatility [Member]
Derivative liability measurment input assumption	163.09%	154.03%	158.74%				158.74%
Measurement Input, Risk Free Interest Rate [Member]
Derivative liability measurment input assumption	2.03%	3.88%	3.88%				3.88%
Measurement Input, Expected Term [Member]
Derivative liability measurment input assumptions	10 years						9 years 1 month 11 days
Measurement Input, Expected Term [Member] | Minimum [Member] | Black-Scholes
Derivative liability measurment input assumptions		2 years 9 months
Measurement Input, Expected Term [Member] | Maximum [Member] | Black-Scholes
Derivative liability measurment input assumptions		9 years 11 months 1 day

STOCK INCENTIVE PLAN (Details N

STOCK INCENTIVE PLAN (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 09, 2022

Sep. 08, 2021

Sep. 04, 2021

Sep. 02, 2021

Aug. 02, 2021

Aug. 22, 2022

Aug. 17, 2021

Apr. 19, 2021

May 29, 2015

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Stock available for issuance

15,881,671

15,881,671

9,806,000

Option granted purchase shares

900,000

13,500,000

Stock option vesting description

5,750,000 vesting immediately and the balance vesting between nine months and a year from issuance

Exercise price

$ 0.10

$ 0.052

Fair value of the option

$ 0.04

Dividend yield

0%

0%

0%

Expected volatility

227%

Risk-free interest rate

3.03%

Expected life

9 years 10 months 24 days

10 years

10 years

Share-based payment arrangement, expense

$ 38,415

$ 517,180

$ 163,641

$ 888,313

Bijan Pedram [Member]

Option granted purchase shares

100,000

Purchase price of stock option

$ 0.67

Stock option vesting description

25% of the Option shares will be vested upon the one anniversary of the vesting commencement day and the balance of the option shares will be vested of thirty-six (36) successive equal monthly in the first anniversary of the vesting commencement day

Jeft Busby [Member]

Option granted purchase shares

1,000,000

Purchase price of stock option

$ 0.60

Stock option vesting description

25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day

Laura M. Periman [Member]

Option granted purchase shares

100,000

Purchase price of stock option

$ 0.64

Stock option vesting description

50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day

Kelly K. Nichols [Member]

Option granted purchase shares

100,000

Purchase price of stock option

$ 0.62

Stock option vesting description

50% of the Option shares will be vested upon the one anniversary of the vesting commencement day and 50% of the Option shares will be vested upon the two anniversaries of the vesting commencement day

Joseph Tauber [Member]

Option granted purchase shares

1,000,000

Purchase price of stock option

$ 0.622

Stock option vesting description

25% of the Option shares will be vested upon the one anniversary of the vesting commencement day, 25% of the Option shares will be vested upon the two anniversaries of the vesting commencement day, 25% of the Option shares will be vested upon the three anniversary of the vesting commencement day and 25% of the Option shares will be vested upon the four anniversaries of the vesting commencement day

2015 Stock Incentive Plan [Member]

Common stock issued under registration statement on form s-8

10,000,000

Increase of issuance shares

40,000,000

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative)					1 Months Ended					9 Months Ended
	Dec. 09, 2022 $ / shares	Jan. 11, 2022 $ / shares shares	Feb. 20, 2019 USD ($) integer shares	Aug. 18, 2016 USD ($) shares	Mar. 31, 2023 USD ($)	Aug. 22, 2022 $ / shares	Mar. 31, 2022 USD ($) shares	Mar. 30, 2022 USD ($) shares	Apr. 16, 2018 shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares shares	Jul. 14, 2022 USD ($)	Jan. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	May 04, 2020 USD ($) $ / shares	Aug. 17, 2016 shares
Preferred stock, shares authorized | shares										5,000,000		5,000,000
Preferred stock, par value per share | $ / shares										$ 0.0001		$ 0.0001
Undesignated preferred stock, shares authorized | shares										4,000,000
Undesignated preferred stock, shares issued | shares										0		0
Undesignated preferred stock, shares outstanding | shares										0		0
Common stock, shares authorized | shares										1,000,000,000		1,000,000,000
Common stock, par value per share | $ / shares										$ 0.0001		$ 0.0001
Common stock shares issued | shares										237,649,403		192,441,917
Common stock, shares outstanding | shares										237,649,403		192,441,917
Common stock to be issued										$ 0		$ 135,000				$ 135,000
Common stock to be issued, per share | $ / shares																$ (0.135)
Exercise price | $ / shares	$ 0.10					$ 0.052
Stock issued upon stock options exercised | shares		282,759
Stock issued during period, shares, stock options exercised | shares		500,000
Share issued for settelment of debt | shares										891,610
Share issued settelment of debt amount										$ 60,000
Loss on settlement debt										$ 4,196
Shares in settlement of claims | shares										3,544,247
Loss on settlement debt										$ 226,171
Value of shares, rights to put or sell, maximum										30,000,000
Subscription receivable										40,000	$ 60,064
Proceeds from convertible notes										575,000	1,325,000
Debt discount										1,790,886		1,583,435
Derivative liabilities							$ 2,054,769			2,373,804	1,995,618	$ 1,648,831			$ 0
January 2022 [Member]
Proceeds from issuance of warrants										$ 75,000
Common stock warrant purchase shares | shares										519,247
Exercise price | $ / shares										$ 0.315
Warrants are exercisable period										3 years
Stock issued during period, shares, restricted shares | shares										302,115
Restricted stock, value, shares issued net of tax withholdings										$ 100,000
Proceeds from convertible notes										177,840
Accrued interest										$ 2,840
Stock issued for severence fees, shares | shares										5,665,636
Stock issued for severence fees, value										$ 349,535
Loss on extinguishment of debt										111,807
Debt discount										167,571
Derivative liabilities										227,459
Theron [Member]
Exchange value										$ 688,432
Shares issued | shares										22,207,486
Equity Purchase Agreement [Member]
Stock issued during period, shares, restricted shares | shares										8,000,000
Restricted stock, value, shares issued net of tax withholdings										$ 234,844
Subscription receivable										46,000
Subscription amount										46,000
Advance received										$ 47,720
Equity Purchase Agreement [Member] | Minimum [Member]
Investment amount													$ 10,000
Equity Purchase Agreement [Member] | Maximum [Member]
Investment amount													$ 250,000
MJNA Investment Holdings, LLC [Member] | Purhase Agreement [Member]
Sale of stock, number of shares issued in transaction | shares			500,000
Sale of stock, consideration received on transaction			$ 500,000
Juniper and Ivy Corporation [Member] | Purchase Agreement [Member]
Cash payments for purchase of preferred stock			65,000
Promissory note issued, face value			$ 435,000
Number of votes per share | integer			100
Third Party [Member]
Stock issued during period, shares, restricted shares | shares								173,390
Restricted stock, value, shares issued net of tax withholdings								$ 32,944
Third Parties 4 [Member]
Stock issued during period, shares, restricted shares | shares							500,000
Restricted stock, value, shares issued net of tax withholdings					$ 79,500
Convertible Preferred Stock Series C [Member]
Preferred stock, shares issued | shares																	500,000
Options exercised during period, exercise price | $ / shares		$ 0.126
Series C Convertible Preferred Stock [Member]
Preferred stock, par value per share | $ / shares										$ 0.0001		$ 0.0001
Preferred stock, shares issued | shares										500,000		500,000
Shares outstanding | shares										500,000		500,000
Series C Convertible Preferred Stock [Member] | MJNA Investment Holdings, LLC [Member]
Preferred stock, shares issued | shares				500,000
Proceeds from issuance of preferred stock				$ 65,000
Series A Preferred Stock [Member]
Preferred stock, shares issued | shares										0
Shares outstanding | shares										0
Series B Preferred Stock [Member]
Preferred stock, shares issued | shares										0
Shares outstanding | shares										0
Stock Purchase Agreement [Member]
Sale of stock, number of shares issued in transaction | shares									1,945,000
Shares issued | shares														519,247
Common stock to be issued							$ 624,290				13,861,004
Cash gross proceeds							$ 55,000				$ 350,000
S 1 Agreement [Member]
Exchange value										$ 452,775
S 1 Agreement [Member] | Third Party [Member]
Stock issued during period, shares, restricted shares | shares										10,750,000	2,227,638
Restricted stock, value, shares issued net of tax withholdings										$ 973,495	$ 78,928
Asset Acquisition [Member]
Asset acquisition amount														$ 7,000,000

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Options outstanding, beginning balance	19,860,715
Options outstanding, ending balance	24,118,329	19,860,715
Weighted average exercise price, beginning	$ 0.049
Weighted average exercise price, ending	$ 0.13	$ 0.049
Equity Option [Member]
Options outstanding, beginning balance	21,860,715	10,960,715
Granted	3,000,000	14,400,000
Exercised		(500,000)
Expired or canceled	(742,386)	(3,000,000)
Options outstanding, ending balance	24,118,329	21,860,715
Weighted average exercise price, beginning	$ 0.049	$ 0.37
Weighted average exercise price, granted	0.02	0.0405
Weighted average exercise price, exercised		0.002
Weighted average exercise price, expired or canceled	0	0.057
Weighted average exercise price, ending	$ 0.13	$ 0.049

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details 1) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
STOCK OPTIONS AND WARRANTS
Weighted average exercise price	$ 0.15	$ 0.15
Options outstanding, beginning balance	24,118,329	19,860,715
Weighted average remaining contractual life	8 years 3 months	9 years
Weighted average exercise price, beginning	$ 0.13	$ 0.049
Number of options exercisable	22,535,024	18,341,741
Options exercisable weighted average exercise price	$ 0.14	$ 0.049

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details 2) - $ / shares		9 Months Ended	12 Months Ended
	Dec. 09, 2022	Sep. 30, 2023	Dec. 31, 2022
STOCK OPTIONS AND WARRANTS
Expected life (years)	9 years 10 months 24 days	10 years	10 years
Risk-free interest rate (%)		3.53%	3.96%
Expected volatility (%)		2.24%	2.29%
Dividend yield (%)	0%	0%	0%
Weighted average fair value of shares at grant date		$ 0	$ 1.74

STOCK OPTIONS AND WARRANTS (D_4

STOCK OPTIONS AND WARRANTS (Details 3) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Options outstanding, beginning balance	19,860,715
Weighted average exercise price, beginning	$ 0.049
Options outstanding, ending balance	24,118,329	19,860,715
Weighted average exercise price, ending	$ 0.13	$ 0.049
Warrants [Member]
Options outstanding, beginning balance	3,544,247	3,025,000
Weighted average exercise price, beginning	$ 0.65	$ 0.71
Granted		519,247
Granted per share	$ 0	$ 0.31
Options outstanding, ending balance	3,544,247	3,544,247
Weighted average exercise price, ending	$ 0.65	$ 0.65

STOCK OPTIONS AND WARRANTS (D_5

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
STOCK OPTIONS AND WARRANTS
Stock-based compensation expense	$ 38,415	$ 517,180	$ 182,215	$ 888,313

COMMITMENT AND CONTINGENCIES (D

COMMITMENT AND CONTINGENCIES (Details)	9 Months Ended
	Sep. 30, 2023 USD ($)
Operating lease one [Member]
Month(s) of term	May 1, 2023 – May 31, 2023
No. Of months	1 year
Monthly base rent	$ 8,014
Total monthly base rent	$ 8,014
Operating lease two [Member]
Month(s) of term	June 1, 2023 – September 30, 2023
No. Of months	1 year
Monthly base rent	$ 8,014
Total monthly base rent	8,014
Conditionally abated monthly base rent	$ 8,014
Operating lease three [Member]
Month(s) of term	July 1, 2023 – April 30, 2024
No. Of months	10 years
Monthly base rent	$ 8,014
Total monthly base rent	$ 8,014
Operating lease four [Member]
Month(s) of term	May 1, 2024 – April 30, 2025
No. Of months	12 years
Monthly base rent	$ 8,335
Total monthly base rent	$ 8,334
Operating lease five [Member]
Month(s) of term	May 1, 2025 – April 30, 2026
No. Of months	12 years
Monthly base rent	$ 8,668
Total monthly base rent	$ 8,668
Operating lease six [Member]
Month(s) of term	May 1, 2026 – May 31, 2026
No. Of months	1 year
Monthly base rent	$ 9,014
Total monthly base rent	$ 9,014

COMMITMENT AND CONTINGENCIES _2

COMMITMENT AND CONTINGENCIES (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
COMMITMENT AND CONTINGENCIES
Weighted-average remaining lease term	2 years 6 months
Right-of-use assets	$ 248,719	$ 19,789
Lease liability obligations, current	91,672
Lease liability obligations, noncurrent	162,410
Total lease liability obligations	$ 254,082
Weighted-average discount rate	6%

COMMITMENT AND CONTINGENCIES _3

COMMITMENT AND CONTINGENCIES (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
COMMITMENT AND CONTINGENCIES
Operating lease expense	$ 26,401	$ 14,854	$ 70,633	$ 37,203
Short-term lease expense	11,637	24,700	34,911	15,516
Total lease expense	$ 38,038	$ 39,554	$ 105,544	$ 52,719

COMMITMENT AND CONTINGENCIES _4

COMMITMENT AND CONTINGENCIES (Details 3)	Sep. 30, 2023 USD ($)
COMMITMENT AND CONTINGENCIES
2023	$ 24,042
2024	106,750
2025	102,684
2026	43,686
Total minimum payments	277,162
Less: amount representing interest	(23,080)
Total	$ 254,082

COMMITMENT AND CONTINGENCIES _5

COMMITMENT AND CONTINGENCIES (Details Narrative)			3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 05, 2020 USD ($)	Jan. 02, 2019 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) ft²	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Salary			$ 30,765	$ 153,102	$ 105,000	$ 275,000
Implicit interest rate					50%
Research and development expenses			34,713	29,722	$ 89,123	109,086	$ 284,869
Land space | ft²					1,908
Monthly base rent			36,765	39,554	$ 70,633	52,719
Maintenance charges			$ 11,637	$ 24,700	34,911	$ 15,516
1st year [Member]
Monthly base rent					4,713
2nd year [Member]
Monthly base rent					4,854
3rd year [Member]
Monthly base rent					$ 5,000
Small Business Innovation Research [Member]
Grant income received							$ 279,981
John W. Huemoeller [Member]
Common stock granted purchase shares | shares		2,000,000
Vesting percentage		50%
Increase salary per month		$ 35,000
CFO [Member]
Increase salary per month		3,000
Stock Purchase Agreement [Member]
Salary		$ 10,000
Implicit interest rate					6%
Purchase price for acquisition					$ 150,468
Small business awarded	$ 395,880

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Oct. 31, 2023
Advance from shareholder	$ 80,170
Subsequent Event [Member]
Additional Stock issued for cash, share		75,000